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1. INTRODUCTION
 NOVEL DRUG DELIVERY SYSTEM
1For many decades treatment of an acute disease or a chronic illness has been 
mostly accomplished by delivery of drugs to patients using various pharmaceutical 
dosage  forms  including  tablets,  capsules,  pills,  suppositories,  creams,  ointments, 
liquids,  aerosols  and  injectables,  as  drug  delivery  systems  are  the  primary 
pharmaceutical  products  commonly  seen  in  the  market,  even  though  these  drug 
delivery system ensure a prompt release of drug, it is necessary to take this type of 
drug several times a day to achieve as well as to maintain the drug concentration with 
in  the  therapeutically  effective  range  needed  for  the  treatment.  This  results  in 
significant fluctuations in drug level.
In the past two and a half  decades several advancements have been made. 
They have resulted in the development of new techniques for drug delivery. These 
techniques are capable of controlling the rate of drug delivery, sustaining the duration 
of therapeutic activity and targeting the delivery of drug to a cell or tissue. Recently 
pulsatile drug delivery system is gaining importance.
These  advancements  have  led  to  the  development  of  several  novel  drug 
delivery systems that could revolutionalise the method of medication and provides a 
number of therapeutic benefits.
2Novel drug delivery system can be broadly divided into two classes:
        1. Sustained release drug delivery system.
        2. Controlled release drug delivery system.
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SUSTAINED RELEASE DRUG DELIVERY SYSTEM:
Sustained  release  drug  delivery  system  is  described  as  a  pharmaceutical 
dosage  form formulated  to  retard  the  release  of  a  therapeutic  agent  such that  its 
appearance in the systemic circulation is delayed and/or prolonged and its plasma 
profile  is  sustained  in  duration.  The  onset  of  its  pharmacological  action  is  often 
delayed and the duration of its therapeutic effect is sustained (e.g. coated granules).
CONTROLLED RELEASE DRUG DELIVERY SYSTEM:
Controlled release drug delivery system has a meaning that goes beyond the 
scope of sustained drug release. It implies a predictability and reproducibility in the 
drug release kinetics. The release of drug ingredients from a controlled release drug 
delivery system proceeds at a rate profile that is not only predictable kinetically but 
also reproducible from one unit to another.
 Controlled release drug delivery system can be classified into four categories:
       1. Rate-Preprogrammed drug delivery system.
       2. Activation-Modulated drug delivery system.
       3. Feedback-Regulated drug delivery system.
       4. Site-Targeting drug delivery system.
[1] RATE-PREPROGRAMMED DRUG DELIVERY SYSTEM
            In this system, the release of drug molecules from the drug delivery system 
has  been  preprogrammed  at  specific  rate  profiles.  This  was  achieved  by  system 
designing which controls the molecular diffusion of drug molecules in and/or across 
the  barrier  medium  with  in  or  surrounding  the  delivery  system.  (e.g.)  implants, 
transdermal system3.
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[2] ACTIVATION – MODULATED DRUG DELIVERY SYSTEM
           The release of the drug molecule from this delivery system is activated by 
some  physical,  chemical  or  biochemical  process  and/or  facilitated  by  the  energy 
supplied  externally.  The  rate  of  drug release  is  then  controlled  by  regulating  the 
process applied or energy input.
Based on the nature of the process applied or the type of energy used, these 
activation modulated drug delivery system can be classified in to three categories:
1. Physical–e.g.:      Osmotic pressure activated drug delivery system-
                                osmotic pump4, iontophoresis activated drug delivery system
2. Chemical- e.g.:     pH activated drug delivery system6                                    
3. Biochemical-e.g.: Enzyme activated drug delivery system7    
 [3] FEED BACK –REGULATED DRUG DELIVERY SYSTEM
The release of the drug molecule from the delivery system is activated by a 
triggering  agent,  such as  biochemical  substance  in  the  body and  regulated  by its 
concentration  viz.  some  feed  back  mechanisms.  The  rate  of  drug release  is  then 
controlled by the concentration of triggering agent detected by a sensor in the feed 
back  regulated  mechanism.  E.g.  bio-responsive  drug  delivery  system,  glucose 
triggered insulin delivery system8.
 [4] SITE-TARGETING DRUG DELIVERY SYSTEM   
In this  system the  drug molecules  are  circumventing  the  other  tissues  and 
moving towards the specific  diseased site and get released.  This will  enhance the 
therapeutic effectiveness and reduces the toxicity to other healthy tissues and improve 
the treatment spectrum e.g. Niosomes, Microspheres. 
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MERITS OF NOVEL DRUG DELIVERY SYSTEM   
1. Improved treatment of many chronic illness where symptom break through 
occurs when the plasma level  of drug drops below the minimum effective 
level.(e.g.) asthma, arthritis
2.  Increased bioavailability 
3. Reduction  in  the  incidence  and severity  of  untoward systemic  side effects 
related to high peak plasma drug concentration.
4. Maintenance of the therapeutic  action of a drug during overnight;  no dose 
periods.
5. Reduction in the total amount of drug administered over the period of drug 
treatment. This contributes to the reduced incidence of systemic and local side 
effects.
6. Production from first pass metabolism and gastro- intestinal tract degradation.
7. Improved patient compliance resulting from the reduction in the number and 
frequency of doses required to maintain the desired therapeutic response.
8. Targeting the drug molecule towards the tissue or organ reduces the toxicity to 
the normal tissues
9. Pulsatile and pH dependent systems release the drug whenever the body 
demands.
10.  Biocompatibility & Economic saving are claimed to be made from better 
disease management achieved with this system. 
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LIMITATIONS OF NOVEL DRUG DELIVERY SYSTEM
Though there are so many advantages in this system there are few factors that 
limit its usage.
1. Variable physiological factors such as gastro intestinal pH enzyme activities, 
gastric and intestinal transit rates, food and severity of patients disease which 
often influence drug bioavailability of conventional dosage forms may also 
interfere which the precision of control release and absorption of drug from 
this system.
2. The products which tend to remain intact may become lodged at some sites. If 
this occurs slow release of drug from the dosage form may produce a high-
localized concentration of drug, which causes local irritation.
3. Drugs having biological half-life of 1 hr or less are difficult to be formulated 
as sustained release formulations. The high rate of elimination of such drugs 
from the body needs an extremely large maintenance dose which provides 8-
12 hrs of continuous therapy.
4. These products normally contain a large amount of drug. There is a possibility 
of unsafe over dosage, if the product is improperly made and the total drug 
contained there in is released at one time or over too short time of interval.
5. If it is once administered it may be difficult to stop the therapy for reasons of 
toxicity or any other.
6. It may be unwise to include potent drugs in such systems.
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TARGETED DRUG DELIVERY SYSTEM (TDDS)
THE CONCEPTS OF TARGETING
• Targeted drug delivery as an event where, a drug-carrier complex/conjugate, 
delivers drugs exclusively to the pre-selected target cells in a specific manner.
• Targeted  drug  delivery  implies  for  selective  and  effective  localization  of 
pharmacologically  active  moiety  at  pre-identified  target  in  therapeutic 
concentration, while restricting its access to non-target normal cellular linings, 
thus minimizing toxic effects and maximizing therapeutic index.
RATIONALE OF DRUG TARGETING
            The site specific targeted drug delivery negotiates an exclusive delivery to 
specific pre-identified compartments with maximum intrinsic activity of drugs and 
concomitantly  reduced  access  of  drug  to  irrelevant  non-target  cells.  The  targeted 
delivery to previously in-accessible domains,  e.g. intracellular sites, virus, bacteria 
and parasites offers distinctive therapeutic benefits. 
The controlled rate and mode of drug delivery to pharmacological receptor 
and specific binding with target cells; as well as bioenvironmental protection of the 
drug en route to the with of action are specific features of targeting. Invariably, every 
event stated contributes to higher drug concentration at the site of action and resultant 
lower concentration at non-target tissue where toxicity might crop-up. The high drug 
concentration at the target site is a result of the relative cellular uptake of the drug 
vehicle, liberation of drug and efflux of free drug from the target site.
              Targeting is signified if the target compartment is distinguished from the 
other compartments, where toxicity may occur, and also if the active drug could be 
placed predominantly in the proximity of target site.
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 The restricted distribution of the parent drug to the non-target site with effective 
accessibility to the target site could maximize the benefits of targeted drug delivery.
•
9Drug targeting is a phenomenon which maneunivers the distribution of drug 
in the body in such a manner  that the major fraction of the drug interacts 
exclusively with the target tissue at a cellular or sub cellular level.
• The  objective  of  drug  targeting  is  to  achieve  a  desired  pharmacological 
response at a selected site without undesirable interactions at other sites.
• This is especially important in cancer chemotherapy and enzyme replacement 
treatment. Drug targeting is the delivery of drugs to receptors or organs or any 
other  specific  part  of  the  body  to  which  one  wishes  to  deliver  the  drug 
exclusively.
• The targeted or site-specific delivery of drugs is indeed a very attractive goal 
because this provides one of the most potential ways to improve therapeutic 
index of the drugs.
• Earlier work done between late 1960s and the mind 1980s stressed the need 
for drug carrier systems primarily to alter the pharmacokinetics of the already 
proven  drugs  whose  efficacy  might  be  improved  by  altering  the  rates  of 
metabolism in liver or clearance by the kidneys. These approaches generally 
were not focused to achieve site specific or targeted delivery such as getting a 
cyto-toxic drug to cancerous tissue while sparing other normal, though equally 
sensitive tissue with the advancement in the carrier technology the issue of 
delivering either individual drug molecule or the entire carrier to the desired 
site has been addressed during the last few year.
• A number  of  technological  advances  have since been made in  the area of 
parenteral drug delivery leading to the development of sophisticated systems 
that allow drug targeting and the sustained or controlled release of parenteral 
medicines.
•
10At present, drug targeting is achieved by one or two approaches. The first 
approach  involves  chemical  modification  of  the  parent  compound  to  a 
derivative which is activated only at the target site.
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• The  second  approach  utilizes  carriers  such  as  liposomes,  niosomes, 
microshpheres,  nanoparticles,  antibodies,  cellular  carriers  (erythrocytes  and 
lymphocytes) and macromolecules to direct drug to its site of action.
• Recent  advancements  have  led  to  the  development  of  several  novel  drug 
delivery  systems  that  could  revolutionize  the  method  of  medication  and 
provides a number of therapeutic benefits.
• The goal of any drug delivery system is to provide a therapeutic   amount of 
drug to the proper site in the body to achieve promptly, and then maintain, the 
desired drug content. The ideal drug delivery systems delivers drug at a rate. 
1. Nanoparticles11, 12
Nanoparticles  are  one  or  several  types  of  systems  known  collectively  as 
colloidal  drug  delivery  systems.  Also  included  in  this  group  are  microcapsules, 
nanocapsules,  macro  molecular  complexes,  polymeric  beads,  micropsheres  and 
liposomes.
A nanoparticle is a particle containing dispersed drug with a diameter of 200 
to 500 nm.  Materials used in the preparation of nanoparticles are sterilisable, non-
toxic  and  biodegradable.  They  usually  are  prepared  by  a  process  similar  to  the 
coacervation  method  of  micro  encapsulation.  Nanoparticles  are  also  called  as 
nanospheres or nanocapsules depending upon whether the drug is in a polymer matrix 
or encapsulated in a cell. The polymers used are the usual bio degradable ones. The 
main advantage of this system is that it can be stored for up to one year and can be 
used for selective target via reticuloendothelial system to liver and to cells that are 
active phagocytically.
2. Niosomes
Nonionic  surfactant  vesicles  known  as  niosomes  are  used  as  carriers  to 
delivery drugs to target organs and modify drug disposition.
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Niosomes  are  found  to  improve  therapeutic  efficacy  of  drugs  in  cancer 
therapy,  parastic,  viral  and  microbial  diseases.  Many  non-  ionic  surfactants  like 
cetrimide,  sodium dodecyl  sulphate  are  used  with  cholesterol  to  entrap  drugs  in 
vesicles.
Livers can act as a depot for many drugs where niosomes containing drug may 
be taken up by the liver where they are broken down by lysosomal lipase slowly to 
release the free drug to the circulation. Niosomes slowly degraded providing a more 
sustained effect.
Niosomes are capable of releasing entrapped drug slowly. Niosomes are found 
to have selective drug delivery potential for cutaneous application of 5- α – dihydro 
testerione triamcinolone acetamide  and intravenous administration  of methotraxate 
for cancer treatment and sodium stilbogluconate in the treatment of lishmaniasis etc.
3. Resealed Erythrocytes
When  erythrocytes are suspended in a hypotonic in a hypotonic medium, they 
sell to about one and half times their normal size and the membrane ruptures resulting 
in  the  formation  of  pores  with  diameters  of  200-  5000A0.   The  pores  allow 
equilibration of the medium then is adjusted to iso-tonicity and the cells are incubated 
at 370C, the pores will close and cause the erythrocytes to reseal. Using this technique 
with a drug present in the extra cellular solution, it is possible to entrap up to 40% of 
the drug inside the resealed erythrocyte and to use this system for targeted delivery 
via intravenous injection.The advantage of using resealed erythrocytes as drug carrier 
is that they are biodegradable, fully biocompatible and non -immunogenic, exhibit 
flexibility  in  circulation  time  depending  on  their  physiochemical  properties,  the 
entrapped drug is shielded from immunologic detection and chemical modification of 
drug is not required. Resealed erythrocytes can be targeted selectively to either the 
liver or spleen, depending on their membrane characteristics. 
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The ability of resealed erythrocytes to deliver drugs to the liver or spleen can 
be viewed as a disadvantage in that other organs and tissues are inaccessible.
4. Microspheres
Microspheres are free flowing powders consisting of spherical particles of size 
ideally less than 125 microns that can be suspended in a suitable aqueous vehicle and 
injected. Each particle is basically a matrix of drug dispersed in polymer from which 
release occurs by a first  order process.  The polymers  used are biocompatible  and 
biodegradable  ex.  Polylactic  acid,  poly  lactidecoglycolide  etc.  Drug  release  is 
controlled by dissolution /  degradation of matrix.  The system is ideally suited for 
controlled release of peptide/ protein drugs.
In order to overcome uptake of intraveneousaly administered microspheres by 
the  reticuloendothelial  system  and  promote  drug  targeting  to  tumours  with  good 
perfusion, magnetic microspheres were developed. They are prepared from albumim 
and magnetite and have size of 1µ g   to permit intravascular injection. 
5. Monoclonal antibodies
Monoclonal antibodies are exceptionally high quality antibodies which consist 
of one molecular  species and which may be obtained in a virtually homogeneous 
state.
Kohler and Milstein in 1975 showed that somatic cell hybridization could be 
used to produce a continuous hybrid cell line producing a single type of anti body. 
The basic principle was to b-lymphocyte from an antigen primed mouse, having the 
ability to secrete a specific antibody and to fuse this with a suitable mouse derived 
plasmacytoma    (often  called  myleom)  line.  The  outcome  was  hybrid  cell  line 
(hybridoma)  which  had  the  phenotypic  properties  of  both  parental  cells,  that  is 
malignancy and specific antibody secretion indefinitely one b- lymphocytes or plasma 
cell is committed to one antibody specificity.
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The discovery of hybridoma technology has been more dramatic than arrival 
of new scientific theory and has revolutionized immunology in a matter of few years.
6. Liposomes
It  is  defined  as  spherule  vesicle  of  lipid  bilayers  enclosing  an  aqueous 
compartment.  The  lipid  most  commonly  used  is  phospholipids,  sphingolipids, 
glycolopids and sterols have been used to prepare liposomes.
           In recent year, liposomes have been extensively studied for their potential to 
serve  as  carriers  for  delivery  of  drugs,  antigens,  hormones,  enzymes  and  other 
biologicals. Because liposomes are composed of naturally occurring substance they 
have the distinct advantage of being nontoxic and biodegradable. Biologically active 
materials  encapsulated  withing  liposomes  are  protected  to  various  extends  from 
immediate dilutions or degradations  in vivo. This protective property promotes the 
delivery of entrapped drugs to the target organ by preventing a premature drug release 
after administration.
Liposomes have two standard forms.Multilamellar vesicles (MLV’s) made up 
of several lipid bilayers separated by fluid. Unilamellar vesicles (ULV’s) consisting 
of single bilayer surrounding an entirely fluid core. The ULV’s are typically 
characterized as being small (SUV’s) or large (LUV’S).
13Limitations of TDDS
TDDS such as liposome’s, resealed erythrocytes and platelets suffer serious 
stability problems.
• Although monoclonal antibodies show very high degree of site specificity the 
selection and isolation procedures are too tough.
• If the particle size of TDDS is high, they may be rapidly cleared by RES.
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• Magnetically controlled TDDS shows high specificity to superficially located 
organs and tissues but cannot be targeted to deep seated organs.
• Monoclonal  antibodies  may  sometimes  cause  unwanted  antigen  antibody 
reaction which leads to serious consequences.
• Microspheres  of  particle  size  more  than  50  µg  can  lead  to  problem  of 
thromboembolisms in general circulation.
• One administered  the  drug  cannot  be  removed  if  an  undesirable  action  is 
precipitated or if the drug is no longer needed.
• Most  of  such systems  are  administered  by subcutaneous  or  intraperitoneal 
route.  The  vehicles  polymer  employed  should  be  sterile,  hydrogen  free, 
nonirritating,  biocompatible  and  biodegradable  and  biodegradable  in  to 
nontoxic compounds within an appropreiate time, preferably close to duration 
of action.
• The products which tend to remain intact may become lodged at some sites. If 
these occur slow release of drug from dosage form leads to a high localized 
concentration of drug which caused local irritation.
• Drugs having biological half life of 1 hr or less are difficult to formulate as 
controlled release formulation.  The high rates of elimination of such drugs 
from the body need an extremely large maintenance dose which provides 8-12 
hrs of continuous therapy.
• As these products normally contain large amount of drug there is possibility of 
unsafe over dosage if the products is improperly made. 
• If it is once administered it may be difficult to stop the therapy due to toxicity 
or any other reasons.
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Merits of TDDS
Targeting of the drug molecule towards the issue or organ reduces the toxicity to 
the normal tissues.
• Increase bioavailability.
• Improved treatment of many chronic illnesses where symptom breaks through 
occurs when the plasma level of the drug falls below the MEC.
• The drug is protected from first pass metabolism and GI degradation. 
• Improved patient compliance can be achieved due to decrease in amount and 
frequency of dose administered. 
• Bio compatibility can be well achieved. 
• Maintenance of therapeutic action of the drug over night.
• Systemic and local side effects are successfully reduced due to the reduction 
in the total amount of the drug.
• Magnetically controlled systems can be used for targeting the drug towards 
superficial tissues.
• Economic savings can be claimed due to reduction of total amount of drug 
used.
Applications of TDDS:
• Red blood cells, leukocytes, lymphocytes and fibroblasts have also been used 
as potential delivery vehicles for drugs. They have an advantage of inherent 
biocompatibility,  but they cannot cross barriers and cannot easily fuse with 
other cells erythrocytes have been explored possible carriers for Methotrexate 
and Adriamycin.
• Many  of  the  more  biocompatible  polymers  can  be  used  as  small  soluble 
molecular drug carriers or they can be assembled as both soluble molecular 
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drug carriers or they can be assembled as both soluble and particulate drug 
vehicles. Large amount of drugs or agents can be incorporated through non- 
covalent forces in the assemble polymers. These particulate system are best 
utilized as sustained release vehicles.
• Bovine album in or bovine serum albumin and human serum albumin have 
been  extensively  investigated  for  target  specific  and  sustained  delivery  of 
cancer chemotherapeutic agents.
• The  intra-peritoneal  administration  of  micro-spheres  sustained  the  drug 
release over a period of time. 
14CARRIER SYSTEMS USED FOR TARGETED DRUG DELIVERY
1. Colloidal carriers
a) Vesiclular system 
    Liposomes; Niosomes; Pharmacosomes; Virosomes; Immunoliposomes.
b) Microparticulate systems 
    Micro particles; Nano particles; Magnetic-micro spheres;
    Albumin micro-spheres; Nano-capsules.
2. Cellular carriers
    Resealed erythrocytes; serum albumin; antibodies; platelets; leukocytes.
3. Supramolecular delivery systems
    Micelles; reverse micelles; mixed micelles; polymeric micelles; 
    Liquid crystals;   Lipoproteins (chylomicron; VLDL; LDL)
    Synthetic LDL mimicking Particles (supramolecule biovector system).
4. Polymer based systems
    Signal sensitive; Muco-adhesive; Biodegradable; Bio-erodible;
    Soluble synthetic polymeric carriers.     
5.  Macromolecular carriers
     a)  Proteins, glycoproteins; neo glycoproteins and artificial viral envelopes (AVE).
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     b) Glycosylated water soluble polymers (poly-L-lysine).
     c)  Mabs; Immunological Fab fragments; antibody-enzyme complex & bispecific 
          Abs.
     d)  Toxins, immunotoxin & rCD4 toxin conjugates. 
     e)  Lectins (Con A) & polysaccharides
LEVELS OF DRUG TARGETING
            Targeted drug delivery may be achieved by using carrier systems, where 
reliance is placed on exploiting both, intrinsic pathway(s) that these carriers follow, 
and the bio-protection that they can offer to drugs during transit through the body. 
The  various  approaches  of  vectoring  the  drug  to  the  target  site  can  be  broadly 
classified as:
1. Passive targeting
2. Inverse targeting
3. Active targeting (Ligand mediated targeting and physical targeting)
4. Dual targeting
5. Double targeting
6. Combination targeting
1) Passive Targeting
           Systems that target the systemic circulation are generally characterized as 
“passive”  delivery  systems  (i.e.  targeting  occurs  because  of  the  body’s  natural 
response to the physicochemical characteristics of the drug or drug-carrier system. It 
is a sort of passive process that utilizes the natural course of (attributed to inherent 
characteristics)  bio-distribution  of the carrier  system,  through which,  it  eventually 
accumulate in the organ compartment of body. 
The ability of some colloids to be taken up by the RES especially in liver and 
spleen has made them as ideal vectors for passive hepatic targeting of drugs to these 
compartments. Passive capture of colloidal carriers by macrophages offers therapeutic 
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opportunities  for  the  delivery  of  anti-infective  for  disease  conditions  that  involve 
macrophage  cells  of  the  reticuloendothelial  system  (RES)  e.g.  leishmaniasis, 
brucellosis  and  candidiasis.  Delivery  into  lysosomal  compartment  can  also  be 
affected  for  the  treatment  of  certain  lysosomal  storage  diseases,  macrophage 
neoplasms and macrophage activation.
            This category of target able devices includes drug bearing bi-layer vesicular 
systems as well cellular carriers of micron or submicron size range. The passive target 
ability of micro particulate drug carriers is due to the recognition of these exogenous 
particulates either in the intact or in the opsonized form, by the phagocyte cells of the 
RES and this sensing behavior is exploited to target MPS associated diseased cell 
lines.
           A major disadvantage of micro particulate carriers is that they cannot pass the 
endothelial cell lines; as a result extravasations are generally poor. Although some 
investigation  claim that  slow Tran cellular  (vesicular)  transport  of liposome’s  and 
micro  spheres  is  possible  through endothelia.  The practical  applications  of  micro 
particulate carriers are largely restricted to intravascular targets. Attempts have been 
made  for  targeting  them  to  intravesicular  non-RES  cell  lines  and  to  increase 
circulation half life by exploiting strategies that involve modification of size, surface 
charge, composition, surface rigidity and surface hydrophilicity. 
           These long circulatory modules can then be relied as carrier base. However, to  
endow them with target specificity some site directing ligands could be appended on 
their  surface  site  specific  ligands  can  be  immobilized  with  optimal  targeting 
efficiency.
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2) Inverse Targeting
             It is essentially based on successful attempts to circumvent and avoid passive  
uptake of colloidal  carriers  by reticuloendothelieal  system (RES).  This  effectively 
leads to the reversion of biodistribution trend of the carrier and hence the process is 
referred to as inverse targeting. 
One strategy applied to achieve inverse targeting is to suppress the function of 
RES  by  a  pre-injection  of  a  large  amount  of  blank  colloidal  carriers  or 
macromolecules like dextran sulphate.This approach lead to RES blockade and as a 
consequence impairment of host defence system.
3) Active Targeting 
            Active targeting exploits modification or manipulation of drug carriers to 
redefinr its biofate. The natural distribution pattern of the drug carrier composites is 
enhanced using chemical, biological and physical means, so that it approaches and 
identified by particular biosites.The facilitation of the binding of the drug-carrier to 
target  cell  through  the  use  of  ligands  or  engineered  homing  devices  toincrease 
receptor  mediated  (or  in  some  cases  receptor  independent  but  epitope  based) 
localization of the drug and target specific delivery of drug is referred to as active 
targeting.
4) Dual Targeting
            This classical approach of the drug targeting employs carrier molecules,  
which have their own intrinsic antiviral effect thus synergies the antiviral effect the 
loaded active drug. Based on this approach, drug conjucates can be prepared with 
fortified activity profile against the viral replication. A major advantage is that the 
virus replication process can be attacked at multiple points, excluding the possibilities 
of resistant viral strain development.
24
5) Double Targeting
         Drug targeting may be combined with passive and active targeting for drug 
delivery  system.  The  combination  is  made  between  spatial  control  and  temporal 
control of drug delivery.
          The temporal control of drug delivery has been developed in terms of control 
drug  release  prior  to  the  development  of  drug  targeting.  If  spatial  targeting  is 
combined with temporal control release results in an improved therapeutics index by 
the following two effects. First, if  drug release or activation is occurred locally at 
therapeutic  sites,  selectivity  with  the  local  release/activation.  Second,  the 
improvement  in  the  therapeutic  index  by  a  combination  of  a  spatially  selective 
delivery and a preferable release pattern for a drug, such as zero order release for a 
longer time period of drugs.
6) Combination Targeting
             These targeting systems are equipped with carriers, polymers and homing 
devices of molecular specificity that could provide a direct approach to target site. 
Modification of proteins and peptides with natural polymers, such as polysaccharides, 
or  synthetic  polymers,  such  as  poly  (ethylene  glycol),  may  alter  their  physical 
characteristics, and favour targeting the specific compartments, organs or their tissues 
within the vasculature. Further vectorization of these modified proteins and peptides 
into vesicular  or  micro-particulate  carriers  may take  advantage  of  the intrinsic  of 
inherited  (through homing devices)  properties  of  carrier  to  achieve  a  site  specific 
active targeting of encapsulated contents.
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THE PENETRATION BARRIER OF THE INTACT SKIN
In the field of the dermal or transdermal drug delivery the skin represents the 
application site and sometimes also the target, but it is the main obstacle for efficient 
drug and/or  carrier  penetration.  The  main  barrier  is  the  so-called  horny layer,  or 
stratum corneum.
Figure No. 1 Structure of skin 
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The skin (cutis) consists of two histologically and functionally different parts: 
The inner part, the dermis, is 10 to 20 times thicker than the outer part, the 
epidermis  that  is  usually  approximately  4  mm  thick.  The  dermis  encompasses  a 
variety of specialized cells, tissues, blood vessels, lymph ducts, glands, hair follicles, 
and sensory and immunocompetent cells. Each of these fulfills a range of important 
tasks. 
One of the important  functions of the dermis  is to nourish the cells of the 
epidermis.  The main function of the epidermis  is  to render  the skin mechanically 
stable and chemically and environmentally resistant; the low permeability is part of 
this. 
           
  The predominant cell type in the epidermis is the keratinocyte. Other cells, such as 
melanocytes  (for  UV  protection),  Langerhans  cells  (for  immune  response),  and 
Merkel cells (part of sensory system) etc., play an important role in the function of 
the skin as well. 
The  keratinocytes  at  the  basal  membrane  of  the  epidermis  continuously 
produce  new cells.  These  then  gradually  move  toward  the  skin  surface  and thus 
replace the shedding cells of the stratum corneum. 
The  stratum  corneum  consists  of  several  layers  of  dead,  flattened  cells 
(corenocytes) embedded into a quasi-lamellar lipid matrix15. Cells originating from 
the same keratinocyte  stem cell  remain  organized in  a  columnar  stack during the 
terminal  differentiation.  Corneocytes  of  neighboring  stacks  interdigitate  at  their 
edges. This structure is often referred to as the “brick and mortar” model of stratum 
corneum; 
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NOVEL METHODS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
New  dosage  forms  and  drug  delivery  systems  providing  excellent 
improvement in drug therapy are termed as novel drug delivery systems .These are 
‘novel’ due to recent development with satisfactory results in field of drug delivery16
Some of these novel advanced transdermal technologies include17:
                    1. Penetration enhancers
                    2. Iontoporesis
                    3. Electroporation and Sonophoresis
                    4. Micro fabricated Micro needles and Microchips
                    5. Vesicular approaches
Figure No – 2 Novel Methods in Transdermal Drug Delivery Systems
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1. PENETRATION ENHANCERS
            Transdermal drug delivery has been a subject of research interest since first  
introduction  of  transdermal  patch of scopolamine  for  motion  sickness18  .The most 
recent developments center on methodologies to increase molecular transport across 
the skin. Much effort has been directed towards the penetration enhancer.
            An ideal enhancer should be pharmacologicaly inactive, non-irritant and 
should not damage skin irreversibly. The effects on the permeation of a drug usually 
depend  upon  the  physio-chemical  characteristics  of  the  permeant  as  well  as  the 
enhancer molecule. The penetration of the enhancer in to stratum corneum is a basic 
requirement for their efficacy. It is possible to facilitate the penetration of the drug by 
appropriate  treatment  of the skin with penetration enhancer19,  the main reason for 
enhancements include:
• Interaction with the intercellular lipids and intracellular keratin 
• Increased penetration of high amounts of enhancers or co-solvents in to
the stratum corneum due to the improved dissolving capacity of the barrier to the 
drugs.  Many  of  the  chemical  enhancers  such  as  dimethyl  sulfoxide,  surfactants, 
alcohols  urea  and  its  derivatives  have  been  screened  for  their  penetration 
enhancement.  terpenes  isolated  from  natural  essential  oils  are  currently  under 
investigation as safe and non irritating penetration enhancer
Terpene enhancers such as L-methanol, D-limonene, methone, carvone, and 
1-8cineole have been used to enhance the transdermal delivery of drugs including 5-
flououracil20, indomethacin, zidovudine and diclofinac sodium. These chemicals have 
exhibited low cutaneous irritation potential and reversible alterations of skin barrier 
function.
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2. IONTOPHORESIS
           The drawbacks associated with chemical enhancers include the unsuitability 
for  delivery  of  new  biotechnological  products  like  peptides,  small  proteins, 
oligonucleotides. Hence a renaissance of interest was shown towards iontophoresis 
developed over the last decade
            Iontophoresis is a process or technique involving the transport of ionic or 
charged molecules in to a tissue by the passage of direct or periodic electric current 
through an electrolyte solution containing the ionic molecules to be delivered using 
an appropriate electrode polarity21. The process involves the transfer of ions into the 
body by an electromotive force.
             Ions with positive charge are driven in to the skin at anode and those with  
negative charge at the cathode. In the conventional topical treatment by iontophoresis, 
the drug is administered through an electrode having the same charge as the drug and 
return electrode opposite in charge to the drug is placed at a neutral site on the body 
surface. The operator then selects a current intensity below the pain threshold level of 
the patient and allows the current to flow for an appropriate period of time22.
             The current intensity should be increased slowly maintained for the length of  
the treatment and decreased slowly at the end of the treatment. the current must be 
within comfortable  toleration of the patient. Interposition of a moist pad between the 
electrode plate and the skin is necessary for making a perfect contact, preventing any 
skin  burns,  overcoming  skin  resistance  and  protecting  skin  from  absorbing  any 
caustic metallic compound formed on the metal plate surface. It is critically important 
that the drug be applied through the electrode with correct polarity, since any reversal 
of the polarity may result in no penetration of the drug. The electrode must not come 
in any direct contact with skin as it may cause burns23.
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            In-spite of its extensive application,  the drawbacks associated with the 
technology include the possibility of electric shock, skin irritation, burns and cost of 
treatment.  Recent  efforts  in  this  technology  have  resulted  in  the  design  of 
iontophoretic electrodes, which avoids burns. The technique has gained acceptance 
for local therapy. Its application for systemic medication will require further research 
to elucidate simple means of drug delivery.  The development of iontophoresis can 
broaden the scope of transdermal delivery to the absorption of poorly absorbed ionic 
drugs.  User  acceptance will  probably depend on success in miniaturization  of the 
assembly.
3. ELECTROPORATION
        The drawbacks associated with chemical enhancers and iontophoresis can be 
overcome to a certain extent by electroporation technology developed in recent years. 
In a more futuristic way, the technology has been developed to overcome the most 
daunting  challenges  of  transdermal  drug  delivery.  The  process  involves  the 
application of transient high voltage electrical pulse to cause rapid dissociation of the 
stratum corneum through which large and small peptides, oligonucleotides and other 
drugs can pass in significant amounts. The degree of enhancement achieved in vitro is 
related to the applied voltage, number and duration of pulses offering the possibility 
of a controllable phenomenon.
       Electroporation is a technique in which the drug encapsulated in vesicles or 
particles is delivered into the skin by applying a pulse causing a breakdown of the 
stratum corneum24. Pressure mediated electroincorporation has been used to deliver 
leuprolide acetate microspheres into hairless mouse skin and human skin xenograflted 
on immunodeficient nude mice. It has been shown that application of continuous low 
voltage resulted in a calcein flux with three orders of magnitude.
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            Beside the model compound calcein, other drugs investigated for transdermal  
delivery by electroporation include metaprolol,  flurbiprofen,  cyclosporine,  heparin, 
fentanyl and oligo-nucleotides25.
            The studies with model compounds have given excellent mechanistic insights  
into the magnitude of flux enhancement. These reports may not be applicable for all 
drugs. Hence each drug needs to be studied as a separate entity. More human clinical 
data is however required before the technology can be commercialized.
4. SONOPHORESIS
            Another  technique besides electroporation attempting to overcome the 
challenges  of  transdermal  drug  delivery  involves  the  usage  of  high  frequency 
ultrasound waves. The application of low frequency ultrasound was shown to increase 
the  permeability  of  human  skin  to  many  drugs  including  high  molecular  weight 
proteins by several orders of magnitude, thus making transdermal administration of 
these molecules  potentially  feasible  Low-frequency ultrasound is  thus  a  potential, 
non-invasive technology for transdermal drug delivery.
          Despite  the excitement  these findings have provoked, it  is  necessary to 
maintain an appropriate perspective until several basic questions are answered with 
respect to mechanism of action,  toxicity,  economical  and technological  feasibility. 
Furthermore, optimal parameters such as frequency, pulse length and intensity should 
be observed carefully to ensure a safe and efficacious application26.
5. MICRO FABRICATED MICRONEEDLES AND MICROCHIPS
            Recently a novel method has been developed for enhancing transport of 
molecules  across  the  skin.  The microfabricated  microneedles  technology employs 
micron-sized needles made from silicon.  These micro-needle arrays  after insertion 
into the skin create conduits for transport of drug across the stratum corneum. The 
drug after crossing the stratum corneum diffuses rapidly through deeper tissue and 
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taken up by capillaries for systemic administration. Micro-needles penetrate the skin 
about 10-15 mm deep inside the skin but do not reach the nerves found in deeper 
tissue, so are painless27. 
The  micro-needles  were  made  using  the  micro  fabrication  technology  is 
simple  for  cheap  and  mass  production  of  micron  sized  structures.  For  the  drug 
delivery, a three-dimensional array of sharp-tipped microneedles with approximately 
150 mm in lengths was fabricated. 
           A deep reactive ion etching process was used to micro-fabricate the needles for 
drug  delivery.  The  reactive  ion  etching  technique  is  based  on  the  black  silicon 
method.  Each  micro-needle  is  about  1  mm in  diameter  or  one  hundredth  of  the 
diameter of a human hair and can be seen only under a microscope. A microprocessor 
is  attached  to  a  tiny  pump  for  delivering  tiny  amounts  of  the  drug.  The 
microprocessor  and  pump  automatically  inject  the  right  dosage  of  the  drug.  The 
micro-needles have extremely sharp tips with radius  of curvature less than 1 mm 
facilitating easy piercing into the skin.
 The micro-fabrication technique can be easily modified to make longer or 
shorter needles according to the requirement. Micro-needles after insertion into skin 
are found to be mechanically strong, can be removed without  difficult  as well  as 
reinserted into skin multiple times. The experiments were also conducted on human 
volunteers by inserting micro-needles into the skin of forearm or hand. 
            As reported, the volunteer never felt pain, but mild wearing or a weak 
pressure with the feeling of a piece of tape affixed to the skin. Inspection of the site 
after insertion showed no erythema, edema or other reaction to micro-needles over 
the hours and days. Micro-needles are still a long way from being marketed. It may 
take  some years  to  perfect  and test  the  technology for  safety and clinical  studies 
before gaining approval from Food and Drug Administration (FDA) 28. 
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6. VESICULAR APPROACHES  
            The encapsulation of drug in lipid vesicles prepared from phospholipids and 
nonionic  surfactant  is  used  for  transport  of  drug  into  and  across  the  skin.  The 
rationale for use of lipid vesicles as a topical drug carrier is as follows29.
• Vesicles  may  serve  as  rate-limiting  membrane  barrier  for  systemic 
absorption of drug.Because of the amphiphilic nature of the vesicles, 
these vesicles may serve as non-toxic penetration enhancer for drugs.
• They may serve as “organic solvent” for the solubilization of poorly 
soluble drugs.
• Vesicles can incorporate both hydrophilic and lipophilic drugs.
              The vesicular approach e.g. liposomes in transdermal drug delivery systems  
have been studied for many purposes, but their  unstable  nature limits  their  use at 
clinical and industrial levels. In order to increase the stability of liposomes concept of 
proliposomes  has  been  proposed.  This  approach  has  been  extended  to  niosomes 
which exhibit superior stability compared to liposomes and attempts have been made 
to further stabilize them and overcome their limitation by proniosomal approach. 
But  all  approaches  because  of  their  poor  skin  permeability,  breaking  of 
vesicles, leakage of drug, aggregation and fusion of vesicles are not much successful 
for effective transdermal delivery30. 
 TRANSFERSOMES
            Poor patient compliance is a frequent problem in daily clinical practice. The 
unfavorable pharmacokinetic of the drug, the inconveniences of the standard form of 
such drug application and the side effects due to the administration route often are the 
reasons for  this.  Consequently much effort  has  been put  into the  development  of 
strategies  that  could  improve  the  patient  compliance  with  new  modes  of  drug 
application. Delivery via the transdermal route is an interesting option in this respect 
because transdermal route is convenient and safe. 
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           This  offers  several  potential  advantages  over  conventional  routes  like 
avoidance  of first  pass metabolism,  predictable  and extended duration  of activity, 
minimizing  undesirable  side  effects,  utility  of  short  half-life  drugs,  improving 
physiological and pharmacological response, avoiding the fluctuation in drug levels, 
inter-and  intra-patient  variations,  and  most  importantly,  it  provides  patient 
convenience. 
But  one  of  the  major  problems  in  transdermal  drug  delivery  is  the  low 
penetration rate through the outermost layer of the skin, the stratum corneum32. To 
date  many  chemical  and  physical  approaches  have  been  applied  to  increase  the 
efficacy  of  the  material  transfer  across  the  intact  skin,  by  use  of  the  penetration 
enhancers, iontophoresis, sonophoresis and the use of colloidal carriers such as lipid 
vesicles (liposomes and pro-liposomes) and nonionic surfactant vesicles (niosomes 
and pro-niosomes).
 Initially various chemical additives (such as alcohols, azones, surfactants etc.) 
were used to increase the lipid fluidity in the outer skin layers and thus improve the 
skin  permeability  to  various  agents.  Use  of  penetration  enhancers  has  some 
limitations like applicable only for low molecular weight drugs(smaller than 500 to 
1000 Da), skin irritation, immunogenicity etc. physical methods like electrophoresis, 
iontophoresis, moreover can transfer some intermediate size charged molecules, but 
the  resulting  overall  material  transfer  efficiency  is  rather  low(less  than  10%),and 
applicable only for charged drug33.
          Vesicular carrier systems like liposomes and niosomes have both received lot 
of attention over the last decade as a means for the transdermal drug delivery. Initially 
the use of liposomes on the skin was reported,  since then a wide range of agents 
loaded in liposomes have been tested on the skin, with different rationalities in mind. 
In  most  cases  transdermal  drug  penetration  has  not  been  achieved.  To 
overcome all the problems mentioned above a new type of carrier system called a 
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“transfersomes”  was  introduced  recently  for  the  effective  transdermal  delivery  of 
number of low and high molecular weight drugs.
        Transfersomes, in the widest sense of the word, is any supramacromolecular 
entity  that  can  pass  spontaneously  through  a  permeability  barrier  and  thereby 
transport material from the application to the destination site. In order to meet the 
goal,  however,  a  tranfersomes  must  adjust  its  properties,  most  notably  its 
deformability to the shape and the size of the pores in the barrier. 
          Tranfersomes, in functional terms, may be described as lipid droplets of such 
deformability that permit its easy penetration through the pores much smaller than the 
droplets’ size. In thermodynamic terms this typically corresponds to an aggregate in 
the quasi-metastable state, which facilitates the formation of highly curved bilayers. 
From  the  composition  point  of  view,  a  transfersomes  is  a  self-adaptable  and 
optimized mixed lipid aggregate34.
           Transfersomes were developed in order to take the advantage of phospholipids 
vesicles  as  transdermal  drug  carrier.  These  self-optimized  aggregates,  with  the 
ultraflexible  membrane,  are  able  to  deliver  the  drug  reproducibly  either  into  or 
through the skin, depending on the choice of administration or application, with high 
efficiency.
These vesicular transfersomes are several orders of magnitudes more elastic 
than  the  standard  liposomes  and  thus  well  suited  for  the  skin  penetration. 
Transfersomes  overcome  the  skin  penetration  difficulty  by  squeezing  themselves 
along the intracellular sealing lipids of the stratum corneum. There is provision for 
this, because of the high vesicle deformability,  which permits the entry due to the 
mechanical stress of surrounding, in a self-adapting manner.
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             Flexibility of transfersomes membrane is achieved by mixing suitable  
surface-active  components  in  the  proper  ratios35.  The  resulting  flexibility  of 
transfersome membrane minimizing the risk of complete vesicle rupture in the skin 
and allows transfersomes to follow the natural water gradient across the epidermis, 
when applied under non-occlusive condition. 
Transfersomes can penetrate the intact stratum corneum spontaneously along 
two  routes  in  the  intracellular  lipid  that  differ  in  their  bi-layer  properties.  The 
following figure shows possible micro-routes for drug penetration across human skin 
intracellular and transcellular36.
            The  high  and  self-optimizing  deformability  of  typical  composite  
transfersomes  membrane,  which  are  adaptable  to  ambient  stress  allow  the  ultra-
deformable transfersomes to change its membrane composition locally and reversibly, 
when  it  is  pressed  against  or  attracted  into  a  narrow  pore.  The  transfersomes 
components  that  sustain  strong  membrane  deformation  preferentially  accumulate, 
which  the  less  adaptable  molecules  are  diluted  at  sites  of  great  stress.  This 
dramatically  lowers  the  energetic  cost  of  membrane  deformation  and permits  the 
resulting, highly flexible particles, first to enter and then to pass through the pores 
rapidly and efficiently. This behavior is not limited to one type of pore and has been 
observed in natural barriers such as in intact skin37.
         
   Natural  transdermal  water  concentration  gradients  consequently  drive  high 
number of the specially designed lipid vesicles  across the hydrophobic  outer skin 
layers.  This  does  not  pertain  to  all  lipid  vesicles,  for  example,  the  available 
transdermal osmotic pressure difference is too low to push the standard lipid vesicles 
(liposomes) through an intact mammalian stratum corneum. Dermally applied lipid 
vesicles can only penetrate into rather than across this region. The reason for this is 
the prohibitively high cost of the standard liposome deformation.  
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              In order to increase the efficacy of vesicle penetration through skin it is  
therefore necessary to minimize this cost for each given vesicles type. It had been by 
adjusting the lipid bi-layer composition until the maximum of the tolerable vesicles 
surface flexibility was achieved. Such an optimization yields transfersomes. Owing to 
their hyperflexibility the latter can transfer as much as 0.1 mg of lipid per hour and 
cm2  across  the  intact  skin,  if  applied  under  suitable  conditions.  Furthermore, 
transfersomes can efficient transepidermal transport of the water soluble substances, 
such as proteins or polypeptides38.
SALIENT FEATURES AND LIMITATIONS OF TRANSFERSOMES
1. Transfersomes  possess  an  infrastructure  consisting  of  hydrophobic  and 
hydrophilic  moieties  together  and  as  a  result  can  accommodate  drug 
molecules with a wide range of solubility.
2.   Transfersomes can deform and pass through narrow constriction from (5 to 
10 times less than their  own diameter)  without measurable loss. This high 
deformability gives better penetration of intact vesicles.
3.  They can act as a carrier for low as well as high molecular weight drugs e.g.  
analgesic,  anesthetic,  corticosteroids,  sex hormone,  anticancer,  insulin,  gap 
junction protein, and albumin. 
4.  They are biocompatible  and biodegradable as they are made from natural 
phospholipids similar to liposomes. 
5. They have high entrapment efficiency, in case of lipophilic drug near to 90%.
6.  They protect the encapsulated drug from metabolic degradation.
7.  They act as depot, releasing their contents slowly and gradually.
8.  They can be used for both systemic as well as topical delivery of drug.
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9.  Easy to scale up, as procedure is simple, do not involve lengthy procedure 
and unnecessary use of pharmaceutically unacceptable additives.
Limitation of Transfersomes
1)  Transfersomes are chemically unstable because of their predisposition to 
oxidative degradation.
2) Purity  of  natural  phospholipids  is  another  criteria  militating  against 
adoption of transfersomes as drug delivery vehicles.
3) Transfersome for formulations are expensive.
 TRANSFERSOMES VS OTHER CARRIER SYSTEMS
           Transfersomes  appear  to  be  remotely  related  to  lipid  bi-layer  vesicle,  
liposomes. However in functional terms, transfersomes differ vastly from commonly 
used liposomes in that they are much more flexible and adaptable.
            The extremely high flexibility of their membrane permits transfersomes to 
squeeze themselves even through pores much smaller than their own diameter. This is 
due to high flexibility of the transfersomes membrane and is achieved by judiciously 
combining at least two lipophilic/amphiphilic components (phospholipids plus bio-
surfactant) with sufficiently different packing characteristics into a single bi-layer. 
The high resulting aggregate deformability permits transfersomes to penetrate the 
skin spontaneously. On the contrary, mixed micelles stay confined to the topmost part 
of the stratum corneum even they are applied non-occlusively39. The reason for this is 
that  mixed  micelles  are  much  less  sensitive  to  the  transepidermal  water  activity 
gradient  than  transfersomes.  (Transfersomes  of  magnitude  (in  size)  greater  than 
standard lipid micelles. Secondly and more importantly, each vesicular transfersomes 
contains  a  water  filled  core  whereas  a  micelle  is  just  a  simple  fatty  droplet. 
Transfersomes thus carry water as well as fat-soluble agent in comparision to micelles 
that can only incorporate lipoidal substances.
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Table No. 1 
Comparison of Different Approaches for Transdermal Drug Delivery
Method Advantage Disadvantage
Penetration
enhancer
Increase penetration through skin and 
give both and systemic  effect 
Skin irritation 
immunogenicity
Only for low molecular 
weight drugs. 
Physical methods 
e.g. iontophoresis
Increase penetration of intermediate 
size charged molecule
Only for charged drugs 
transfer efficiency is 
low 
Liposome's Phospholipid vesicle, Provide sustained 
release, biocompatible, biodegradable 
Less skin penetration 
Less stable suitable for 
topical delivery 
Proliposomes More stable than liposome’s Less skin penetration
Niosomes Non-ionic surfactants vesicles, greater 
stability, easy handling 
Less skin penetration
Transfersomes More stable, high penetration due to 
high  deformability  Biocompatible 
and biodegradable, suitable for both 
low and high molecular weight and 
also  for  liphophilic  as  well  as 
hydrophilic and reaches up to deeper 
skin layers.
None,  but  for  some 
limitations  like  the 
higher cost stability of 
the formulations.
Table No. 2 
40
APPLICATION OF TRANSFERSOMES AS A DRUG CARRIER
Drug Results
Insulin40
Interferon-ά41
Interleukin-2
Soluble proteins42-46
Gap junction protein
Human serum albumin
Integral membrane protein
Corticosteroids47,48 
Hydrocortisone
Triamcinolone acetonide
Topical  analgesic  and  anesthetic 
agent49.50 
Diclofenac,Tetracaine,Lidocaine
Oestradiol 51,52
Tomoxifen53
Norgesterol54
Cyclosporine55
Dexamethasone56,57
High encapsulation efficacy
Transfer across the skin with an efficacy of 
>50%  Provide  noninvasive  means  of 
therapeutic use
Efficient delivery means(because delivery by 
other route is difficulty
Controlled release
Overcome stability problem
Permits  non-invasive  immunization  through 
normal skin
Antibody  titer  is  similar  or  even  slightly 
higher than subcutaneous injection
Improve  site  specificity  and  overall  drug 
safety
Biologically  active  at  dose  several  times 
lower than the currently used formulation
Used both for local and systemic delivery
Suitable means for the noninvasive treatment 
of  local  pain  on  direct  topical  drug 
application.
Prolonging drug action
Improved transdermal flux
Provide controlled release
Improved transdermal flux
Reduce drug toxicity
Improved transdermal permeation
Reduce side effects
Improved therapeutic efficacy
Prolonging drug action
Improved transdermal flux
Prolonging drug action
Table No. 3
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SOME EMERGING VESICULAR SYSTEMS
S.No Vesicular 
systems
Description Application Reference
1 Enzymosomes Liposomal  constructs 
engineered  to  provide  a  mini 
bio-environment  in  which 
enzymes  are  covalently 
immobilized or coupled to the 
surface of liposomes. 
Targeted 
delivery  to 
tumor cells
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2 Virosomes Liposomes  spiked  with  virus 
glycoprotein  ,  incorporated 
into  the  liposomal  bilayers 
based on retro viruses derived 
lipids.
Immunological 
adjuvants
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3 Ufasomes Vesicles  enclosed  by  fatty 
acids  obtained  from  long 
chain  fatty  acids  (oleic  acid, 
linoleic  acid)  by  mechanical 
agitation  of  evaporated  films 
in  the  presence  of  buffer 
solutions.
Ligand 
mediated  drug 
targeting
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4 Cryptosomes Lipid  vesicles  with a  surface 
coat  composed of  PC and of 
suitable  polyoxyethylene 
derivative  of  phosphatidyl 
ethanolamine.
Ligand 
mediated  drug 
targeting 61
5 Emulsomes Nanosize  lipid  particles 
(bioadhesive  nanoemulsion) 
consisted of microscopic lipid 
assembly with apolar core.
Parenteral 
delivery  of 
poorly  water 
soluble drugs .
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6 Discomes Niosomes  solubilized  with 
non-ionic  surfaccant 
solution(polyosyethylene 
cetyl ether class)
Ligand 
mediated  drug 
targeting
63
7 Aquasomes Three  layered  self-assembly 
compositions  which  ceramic 
carbon-nanocrystalline 
particulate  core  coated  with 
glassy cellobiose.
Specific 
targeting, 
molecular 
shielding.
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8 Ethosomes Ethosomes  are  lipid  “soft, 
malleable esicles” embodying 
a  permeation  enhancer  and 
composed  of  phospholipids, 
ethanol and water.
Targeted 
delivery to deep 
skin layers
65
9 Genosomes Artifical  macromolecular Cell  specific 66
42
complexes for functional gene 
transfer.  Cationic  lipids  are 
most  suitable  because  they 
possess  high  biodegradability 
and  stability  in  the  blood 
stream.
gene transfer
10 Photosomes Photolyase  encapsulated  in 
liposomes,  which  release  the 
contents,  by  photo-  triggered 
charges  in  membrane 
permeability characteristics.
Photodynamic 
therapy
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11 Erythrosomes Liposomal  systems  in  which 
chemically  crosslinked 
humanery  throcytes 
cytoskeletons  are  used  as  a 
support to which lipid bilayer 
is coated.
Effective 
targeting  of 
macromolecular 
drugs 
68
12 Hemosomes Haemoglobin  containing 
liposomes  engineered  by 
immobilizing  haemoglobin 
witha  polymerisable 
phospholipids.
High  capacity 
oxygen  carrying 
system.
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13 Proteosomes High molecular weight multi-
subunit  enzyme  complexes 
with  catalytic  activity,  which 
is  specifically  due  to  the 
assembly pattern of enzymes.
Better  catalytic 
activity  turn 
over   than non-
assciated 
enzymes.
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14 Vesosome Nested  bilayer  compartments 
in  vitro  via  the 
“interdigitated”  bilayer  phase 
formed by adding ethanol to a 
variety  of  saturated 
phospholipids.
Multiple 
compartments 
of the vesosome 
give  protection 
to  interior 
contents  in 
serum.
71
15 Archaeosomes Vesicles  composed  of 
glycerolipids  of  archaea  with 
potent adjuvant activity.
Potent  adjuvant 
activity.
72
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 DIABETES MELLITUS73-74
Diabetes mellitus is a condition in which the body cells are no longer able to 
utilize blood sugar. Blood sugar is the fuel that cells use to make energy. Symptoms 
of  diabetes  mellitus  include  excessive  thirst  and  hunger,  frequent  urination,  and 
tiredness.
Diabetes  mellitus  is  a  chronic  health  disorder.  Chronic  means  that  the 
condition lasts for many years. Diabetes can cause serious health problems. These 
problems include kidney failure, heart disease, stroke, and blindness. About fourteen 
million Americans have diabetes. As many as half of these people do not know they 
have the condition.
Diabetes Mellitus: words to know
Glucose:
 A type of sugar that is present in the blood and in cells, used by cells to make 
energy.
Insulin:
  Hormone (type of protein) produced by the pancreas than makes it possible 
for cells to glucose in the production of energy.
Ketoacidosis:
 A  condition  that  results  from  the  build-up  of  toxic  chemicals  known  as 
ketones in the blood.
Pancreas:
A gland located behind the stomach that produces insulin.
The energy your body needs:
        Our bodies require a constant production of energy.  We use that energy to 
walk, talk, think, and carry on many other activities. The energy comes from the food 
we  eat.  Certain  foods  contain  chemicals  known  as  carbohydrates.  When 
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carbohydrates  enter  the body,  they break down to form a simple  sugar known as 
glucose. The glucose travels to cells throughout the body by way of the bloodstream.
             To enter a cell, glucose may need the help of another chemical known as  
insulin.  Insulin  is  produced  in  the  pancreas.  Insulin  also  travels  through  the 
bloodstream to all cells in the body. It acts like a key that opens cells so that glucose 
can enter. In a healthy body, enough insulin is produced to make sure that all cells get 
the glucose they need. The cells can then produce enough energy to satisfy the body’s 
needs.
           In some cases, however, this system breaks down. One problem may be that  
the pancreas stops producing enough insulin. There is not enough insulin for all the 
cells that need it. Glucose cannot get into many of the body’s cells. The cells cannot 
produce enough energy for the body’s needs. Another problem is that some cells may 
no longer recognize insulin. The pancreas may still produce insulin for all the body’s 
cells, but some cells don’t respond to it. Again, glucose can’t get into the cells and 
energy is not produced to satisfy the body’s needs.
 TYPES OF DIABETES MELLITUS
           Two types of diabetes mellitus are recognized. These two types differ in two 
major ways-the age at  which they occur and their  causes.  Type I  diabetes  is  also 
called juvenile diabetes. It usually begins during childhood or adolescence. In this 
form of diabetes,  the pancreas produces little  or no insulin.  The condition can be 
treated by having a person take daily injections of insulin. For this reason, Type I 
diabetes is also called insulin-dependent diabetes. Type I diabetes affects about three 
people in one thousand in the United States. 
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            In type 1 the pancreas undergoes an autoimmune attack by the body itself, and 
is rendered incapable of making insulin. Abnormal antibodies have been found in 
patients  with  type1  diabetes.  It  is  believed  that  the  tendency  to  develop  these 
abnormal antibodies is in part genetically inherited. The gene foe developing type 1 
diabetes has been identified on chromosome no11. type 1 diabetes tends to occur in 
young, lean individuals, usually before 30 years of age, however, older patients do 
present with this form on occasion. Totally 90% of the diabetic patients were affected 
with type2 and remaining 10% with Type1 diabetes.
            Type II diabetes is sometimes called adult-onset diabetes. The name “adult-
onset”  comes  from the fact  that  Type  II  diabetes  usually  does not  appear  until  a 
person grows older. More than 90 percent of the disorder is not caused by low levels 
of insulin. Instead, the body’s cells do not recognize insulin in the bloodstream. They 
are not able to get the glucose they need to make energy. People with Type II diabetes 
do not need to take insulin. Their body produces all the insulin it needs. The body just 
can’t use it properly. As a result, Type II diabetes is sometimes called non insulin-
dependent diabetes .Type II diabetes is treated with diet, exercise, and drugs.
CAUSES  
           The causes of diabetes mellitus are unclear. Both heredity and environment 
may be involved. Studies have shown that certain genetic factors may be responsible 
for diabetes. Genes are chemical units found in all cells, that tell cells what functions 
they should perform. Genes are passed down from parents to children. If parents carry 
a gene for diabetes, they may pass that gene on to their children.
        Some researchers believe that Type I diabetes may also be caused by a virus or  
some  other  disease-causing  organism.  They  think  the  organism  may  attack  the 
pancreas at an early age. The pancreas may be damaged and lose its ability to produce 
insulin.
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     A number of factors have been tied to Type II diabetes. These factors include:
• Obesity (being excessively overweight, see obesity entry)
• Having relatives with diabetes mellitus
• Belonging to certain high-risk populations, such as African Americans, 
Native Americans, Hispanics, or Native Hawaiians having high blood 
pressure
• Having an excess or deficiency of certain substances in the blood, such 
as cholesterol or triglycerides (a form of fat)
SYMPTOMS
            The classic symptoms of diabetes include being overly tired and sick, having 
to urinate frequently,  feeling very thirsty and hungry,  and losing weight. The way 
these symptoms develop differs for Type I and Type II diabetes. In Type I diabetes, 
they usually show up slowly in children or adolescents over a period of a few days or 
weeks. In Type II diabetes, they develop even more slowly, over a period of years, in 
adults over the age of forty. Adults often do not realize they have diabetes mellitus. 
The condition  may be  discovered  only during a  routine  physical  examination  for 
some other problem.
         Type I diabetes is generally a more serious condition than Type II. The most 
dangerous effect of Type I diabetes is a condition known as ketoacidosis (pronounced 
KEE-toe-ASS-ih-doe-sus), which occurs when Type I diabetes is not controlled. In 
ketoacidosis, chemicals that are toxic (poisonous) to the body begin to collect in the 
blood. These chemicals can cause abdominal pain, vomiting, rapid breathing, extreme 
tiredness, and drowsiness. If this condition is not treated, a person may fall into a 
coma and die.  The most  characteristic  symptom of ketoacidosis  is  sweet-smelling 
breath.
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The symptoms of Type II diabetes usually develop more slowly and are less 
serious. In the worst circumstance, they include heart disease, infections of the gums 
and urinary tract,  blurred vision,  numbness  in the feet and legs, and slow-healing 
wounds.
 DIAGNOSIS
 
           A patient with the symptoms listed above may be suspected of having diabetes. 
The diagnosis can be confirmed very easily and quickly with a blood and/or urine 
test. The amount of glucose present in the blood or urine can be measured. If the level 
is unusually high, it is likely the person has diabetes.
The  simplest  test  for  diabetes  uses  paper  strips  that  change  colour  when 
dipped into urine. The color of the strip is compared to a chart that comes with the 
strips. The chart shows how much glucose is present in the urine.
           Blood tests can also be used to test for glucose. These tests tend to be more  
accurate than urine tests. A sample of blood is taken from the patient’s  arm.  The 
sample is then analyzed in a laboratory. The amount of glucose present is determined. 
That amount is compared with the amount present in a healthy person’s blood. A high 
level of glucose suggests the presence of diabetes.
            People with diabetes often test their own blood many times a day. They use 
home glucose test kits that contain a small needle and a chart. They use the needle to 
produce a single drop of blood (often from their fingertip). The drop is then placed on 
a  spot  on the chart  that  contains  a chemical  that  reacts  with glucose.  The colour 
produced on the spot can be compared to the chart. It shows the level of glucose in 
the blood.
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TREATMENT
       There is currently no cure for diabetes. However, the condition can be managed 
well enough to allow most people to live normal lives. Treatment of diabetes focuses 
on two goals. The first is to keep blood glucose within a normal range, and the second 
is to prevent complications from developing over time.
Lifestyle Changes for Treatment of Type II Diabetes
       Obesity is one of the major causes of type II diabetes. Therefore, controlling  
one’s weight is an important step in controlling the disorder. Type II diabetics are 
advised to have a well-balanced, nutritious diet and to follow a program of moderate 
exercise.
The goal in diet planning is to limit one’s intake of calories. 
             The term calories are used to describe the energy content of foods. If one  
takes in too many calories, they are not used to produce energy. They are converted 
into fat, which is stored in the body. The number of calories a person should take in 
each day depends on a number of factors, such as age, weight, and level of activity. 
Many professional organizations have developed diet plans for people with type II 
diabetes.  These plans  insure that  people get all  necessary nourishment.  They also 
insure that people do not eat more calories than needed for daily activities.
Oral Medications for Type II Diabetes 
             A number of drugs have been developed for the treatment of Type II diabetes. 
Most  of these drugs  belong to a class  of compounds known as  the sulfonylureas 
(pronounced  SULL-fuh-nil-u-ree-uhz).  They  include  tolbutamide,  tolazamide, 
acetohexamide,  andchlorpropamide.  These  drugs  stimulate  the  pancreas  to  make 
more insulin.
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           These drugs all have side effects. For example, they may cause a person to 
gain weight. But weight gain is often the original cause of the problem for Type II 
diabetics. So the drugs may not be very useful. They are still not as satisfactory as a 
well-planned diet and program of exercise. The drugs are also not effective against 
Type I diabetes.
Treatment of Last Resort: Surgery
            In extreme cases, a pancreas transplant may be performed. In this procedure,  
the  patient’s  own pancreas  is  removed  and a  healthy  pancreas  substituted.  If  the 
surgery is successfully, the healthy pancreas begins producing insulin in the patient’s 
body.
Surgery is often a treatment of last resort. Any surgical procedure has many 
risks involved. A doctor wants to be certain that those risks are worth the benefit the 
patient will gain by having a new pancreas.
 Prognosis  
         In most patients, diabetes can be controlled by diet,  exercise, and insulin 
injections. If the condition is not treated, however, some serious complications may 
result. For example, uncontrolled diabetes is the leading cause of blindness, kidney 
disease, and amputations of arms and legs. It also doubles a person’s risk for heart  
disease and increases the risk of stroke. Eye problems also occur more commonly 
among diabetics than in the general population.
Some other long-term effects of diabetes mellitus include the following:
Loss of sensitivity in certain nerves, especially in the legs and feet.
Foot ulcers   
• Delayed healing of wounds
• Heart and kidney disease
There is currently no way to prevent Type I diabetes. The risk for Type II diabetes 
can be reduced, however, by maintaining an ideal weight and exercising regularly.
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2. REVIEW OF LITERATURE
 Subheet  Jain,  Rachna  Sapre et  al75  had  studied  the  protransfersome  gel 
formulations  of  levonorgestrel  were prepared and characterizied  for  shape, 
size  entrapment  efficiency,  and  drug permeation  across  rat  skin  and were 
evaluated  for  their  stability  results  indicated  that  the  optimized 
protransfersomes  formulation  of  levonorgestrel  had  better  skin  permeation 
potential,  sustained  release  characteristic,  and  better  stability  than  pro-
liposomal formulation.
 Jianxin Guo, Qineng ping et al76 had studied two kinds of vesicles with and 
without the presence of sodium cholate was prepared, using cyclosporine as a 
drug. When applied onto the excised abdominal skin of mice non-occlusively, 
the enhancing effects  of vesicles on the penetration of cyclorporin A were 
assessed by an in-vitro permeation technique. In conclusion, flexible vesicle is 
better  than  conventional  vesicle  as  the  carrier  for  transdermal  delivery  of 
cyclosporine was observed.
 Gamal M. Brian W .Barry et al77 have screened lipid vesicles improved in-
vitro skin delivery of the lipophilic drug, oestradiol, compared with saturated 
aqueous solution; deformable vesicles were superior to traditional liposomes. 
Deformable  vesicles  and  traditional  liposomes  were  compared  as  delivery 
systems for oestradiol to elucidate possible systems for oestradiol to elucidate 
possible mechanisms of drug delivery through human skin observed.
 S.Jain, R.B. Umamaheswari,  et  al78 reported as a review article  of ultra-
deformable liposomes: a recent tool for effective transdermal drug delivery. In 
this review the theoretical prospect, basic principle behind the development, 
mechanism of penetration and applications of transfersomes were studied.
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 S.S.Biju,  Sushama  Talegaonkar  et  al79  reported  as  a  review  article  of 
vesicular systems.  The focus of this  review is to bring out the application, 
advantages, and drawbacks of vesicular systems.
 Christian  Hofer,  Roland  Gobel  et  al80  have  screened  transfersomes  are 
highly deformable hydrophilic lipid vesicles that are able to penetrate the skin 
barrier spontaneously because of their characteristics. Transfersomes are able 
to transport non-invasively low and high molecular weight molecules into the 
body.  It  was  possible  to  incorporate  a  large  amount  of  interleukin-2  and 
interferon-f in transfersomes and the incorporate interleukin-2 and interferon-f 
were biologically active.
 Prem N Gupta, Vivek Mishara et al81 had studied proteineous antigen alone 
or in combination with conventional bioactive carriers penetrate through the 
intact  skin.  Hence,  specially  designed,  deformable  lipid  vesicles  called 
transfersomes were used in this study for the non-invasive delivery of tetanus 
toxoid.  Transfersomes  were  prepared  and  characterized  for  shape,size, 
entrapment efficiency and deformability index were also discussed.
 Mahor S et al82 explain about the potential cationic transfersomes as DNA 
vaccine  carriers  for  effective  topical  immunization.  Cationic  transfersomes 
were prepared optimized for their size, shape, zeta-potentials, deformability 
and  loading  efficiency.  The  immune  stimulating  activity  was  studied  by 
measuring serum anti-HBS Ag administered intramuscularly.
 Benson G et al83 had studied development and evaluation of transfersomes 
and elastic vesicles as topical and transdermal delivery system. Transfersomes 
are applied in a non-occluded method to the skin and have been shown to 
permeate through the stratum corneum lipid lamellar regions as a result of the 
hydration or osmotic force in the skin. They have been used as drug carriers 
for range of small  molecules,  peptides, proteins and vaccines,  both  in-vitro 
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and in-vivo. Using the principle of incorporating an edge-activator agent into a 
bi-layer  structure,  a number of other elastic  vesicle composition have been 
evaluated.
 Zhengy  B  et  al84 had  studied  the  influence  of  drug  properties  on  the 
encapsulation  efficiency  and  drug  release  of  transfersomes  for  a  proper 
transfersome preparation. To prepare the transfersomes of colchicines (CLC), 
vincristine sulfate (VCR) and mitoxancrone hydrochloride (DHAD) with the 
same  materials  and  methods,  and  then  measures  their  encapsulation 
efficiency.  To  perform  the  drug  release  experiments  of  various  types  of 
transfersomes  in-vitro,  and compare their differences. VCR and DHAD are 
lipophilic or hydrophilic, owing positive charges and large molecular weight, 
as a result, their EE is high. CLC is amphipathic, neutral and small molecular 
weight, it encapsulation efficiency is very low. The present study suggested; 
to prepare transfersomes with high EE,drugs that are lipophilic or hydrophilic, 
high  molecular  weight  and  opposite  charges  to  the  membrane  should  be 
chosen. Interaction between drugs and membrane will influence the rate of 
drug release.
 Long  XY  et  al85  had  studied  capsaicin  transfersome  prepared  entrapment 
efficiency of capsaicin transfersomes reached 96.7%, meeting the criterion of 
china pharmacopic(>80%), skin penetration of capsaicin was enhanced by a 
capsaicin transfersomes preparation and was affected  by diverse characters 
and levels of skin. By high shear dispersing machine and evaluated on the 
entrapment efficiency, drug release rate and in-vitro skin permeation.
 Huy J  et  al86, explains  about  tanshinone  transfersome  were  prepared  and 
evaluated for its  deformability.  Tanshinone transfersomes prepared by film 
dispersion method has good entrapment efficiency and stability. The vesicles 
possess high deformability in relation to the molar ratio of sodium cholate to 
lecithin and external pressure.
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 Lu  Y  ,  et  a87., demonstrated  that  preparation  method  of  vincristine 
transfersomes  and  predicts  its  possibility  of  being  a  new  formulation  of 
vincristine  transfersomes.  Orthogonal  design  was  used  to  optimize  the 
preparation methods on the basis of single factor pretests; and the permeation 
tests  invitro were performed in modified  Franz diffusion cells.  The test  in  
vitro showed that  vincristine  transfersomes  could  permeate  through mouse 
skin  at  zero  Srates  with  the  cumulative  penetrating  quality  amounting  to 
63.8%.
 Gupta  PN  et  al88, reported  that  elastic  vesicle  transfersomes,  non-ionic 
surfactant vesicles (niosomes) and liposomes were used to study their relative 
potential  in  non-invasive  delivery  of  tetancy  toxoid  (TT).  Tansfersomes, 
niosomes and liposomes were prepared and characterized for shape, size and 
entrapment  efficiency.  These vesicles were extruded through polycarbonate 
filter (50-nm) to assess the elasticity of the vesicles. The immune stimulating 
activity of transfersomes, niosomes, and liposomes were studied by measuring 
the serum anti-tetanus toxoid IgG titre following topical immunization.  In-
vivo  study  revealed  that  topically  given  tetanus  toxoid  containing 
transfersomes,  after  secondary immunization,  could elicit  immune response 
(anti-TT-IgG)  that  was  equivalent  to  one  that  produced  following 
intramuscularly  alum-adsorbed  tetanus  toxoid  based  immunization.  In 
comparision  to  transfersomes,  niosomes  and  liposomes  elicited  weaker 
immune response. Thus transfersomes hold promise for effective non-invasive 
topical delivery of antigen.
 Cevc G. et al89 had studied insulin-loaded transfersomes,  for example,  can 
deliver  the  drug  through  the  non-compromised  skin  barrier  with  a 
reproducible drug effect that resembles closely that of an ultra-lente insulin 
injected under the skin; the pharmacokinetic and pharmacodynamic properties 
of  the  injected  and  transdermal  insulin  are  also  comparable.  Systemic 
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normoglycaemia that lasts at least 16-hours has been achieved using a single 
non-invasive, epicutaneous administration of insulin in transfersomes.
 Cevc  G,  Blume  G  et  al90, reported  that  Diclofenac  association  with 
ultradeformable carriers permits it to have a longer effect and to reach 10-
times higher concentration in the tissues under the skin in comparision with 
the drug from a commercial hydrogel. The relative advantage of diclofenac 
delivery  by  means  of  ultra-deformable  carriers  increases  with  the  treated 
muscle thickness and with decreasing drug close, as seen in mice,  rats and 
pigs. When the drug is used in a hydrogel at 8 times higher dose, the average 
intramuscular concentration is at least three times lower and subtherapeutic. 
This  suggests  that  diclofenac  in  transfersomes  has  the  potential  to  replace 
combined oral/topical diclofenac administration in humans.
 Bhatia A, et al91, reported that multilamellar  liposomes of tamoxifen were 
prepared  by  thin  film  hydration  method.  Various  formulation  (lipid 
composition, drug-lipid ratio, amount and type of surfactant etc.) and process 
parameter (hydration temperature, hydration time etc) were studied to obtain 
liposomes with desired attributes. Tamoxifen molecules could be successfully 
entrapped in the liposomes with reasonable drug-loading and desired vesicle 
specific characters. Higher rate of drug transfer across the skin with liposomal 
formulation of tamoxifen, suggests that the drug in its lipo-solubilised state 
might have found facilitated entry into the tough barrier consisting of stratum 
corneum. The phospholipids enriched amphiphillic nature of the vesicles can 
be held responsible for modifying the properties of the keratinized layer.
 Jains C et al92, reported that evaluating the transdermal route as an alternative 
to the oral route for improving the systemic bioavailability and sustaining the 
constant  therapeutic  plasma  level  of  zidovudine(AZT).  Elastic  liposomal 
formulations of AZT were prepared and characterized. The effect of different 
formulation variables on transdermal delivery of AZT from elastic liposomes 
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was  studied.  These  elastic  liposomes  increased  the  transdermal  flux, 
prolonged the release, improved the site specificity of AZT and represented an 
attractive strategy for sustained and targeted delivery of AZT.
 Gaspar MM et al93, shows that biological behavior of Acylated superoxide 
Dimutase  (AC-SOD)  inserted  into  the  lipid  bi-layer  of  liposomes,  in 
comparison  with  SOD  located  in  the  aqueous  compartment  of  liposomes 
conventional liposomes presenting an unmodified external surface and long 
circulating liposomal formulations of AC-SOD and SOD were prepared and 
labeled  with  indium-III  and  their  in-vivo fate  was  not  influenced  by  the 
insertion of AC-SOD in the lipid bi-layers. The potential therapeutic effect of 
AC_SOD enzymosomes was compared with SOD liposomes in a rat model of 
adjuvant  arthritis.  A  faster  anti-inflammatory  effect  was  observed  for 
AC_SOD enzymosomes by monitoring the volume of the inflamed paws. The 
present results allowed us to conclude that AC-SOD enzymosomes are nano-
carriers combining the advantages of expressing enzymatic activity in intact 
form and thus being able to exert therapeutic effect even before liposomes 
disruption, as well as acting as a sustained release of the enzymes.
 Touitou E et al94, have screened ethosomal systems been much more efficient 
at delivering a fluorescent probe to the skin in terms of quantity and depth, 
than  either  liposomes  or  hydro-alcoholic  solution.  The  ethosomal  system 
dramatically  enhanced  the  skin  permeation  of  minoxidil  in-vitro compared 
with either  ethanolic  or  hydroethanolic  solution  or  phospholipids  ethanolic 
micellar  solution  of  minoxidil.  In  addition,  the  transdermal  delivery  of 
testosterone from an ethosomal patch was greater both  in-vitro and  in-vivo 
than  from  commercially  available  patches  skin  permeation  of  ethosomal 
components,  ethanol  and  phospholid,  was  demonstrated  in  diffusion  cell 
experiment.  Experiments  using  fluorescent  probes  and  ultracentrifugation 
showed that the ethosomes had a high entrapment capacity for molecules of 
various lyophilicities.
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 Elsayed MM et  al95, have  screened  deformable  liposomes  and  ethosomes 
improve  skin  delivery  of  ketotifen  under  non-occlusive  conditions  were 
investigated.  In-vitro permeation and skin deposition behavior of deformable 
liposomes  and  ethosomes,  having  ketotifen  only  inside  the  vesicles  (free 
ketotifen separated) and having ketotifen only outside the vesicles (Ketotifen 
solution added to empty vesicles), was studied using rabbit pinna skin. Results 
suggested deformable vesicles might play a role in improving skin delivery of 
drugs  under  non-occlusive  conditions,  and  that  the  penetration  enhancing 
effect  was  greater  importance  incase  of  ketotifen.  Regarding  ethosomes, 
results indicated that ketotifen should be incorporated in ethosomes vesicles 
for optimum skin delivery.
 Giuseppe Derosa et al96, have screened to evaluate the expected improvement 
in  glucose  and  lipid  metabolism  obtainable  with  doxazosin  is  or  is  not 
synergistic  with  standard  anti-hyperglycaemic  treatment  using  the  α-
glucosidase inhibitor acarbose. Evaluated 107 patients with impaired glucose 
tolerance  (IGT) as  determined by oral  glucose tolerance  tests.  All  patients 
took a fixed close of acarbose 150mg/day for 3 month. In addition, patients 
were randomized  to  either  placebo or  doxazosin  4mg/day for  the  entire  6 
month  treatment  period.  Parameters  were  evaluated  during  the  6-month 
treatment period include body mass index, glycaemic control, fasting plasma 
etc.  it  was  concluded  that  doxazosin  given  in  combination  with  Acarbose 
seemed to improve gly-caemic and lipid control compared with placebo in 
patients with IGT.
 Cyndya  snibao et  al97, reported  the  effectiveness  of  acarbose  for  the 
treatment of post-prandial hypotension in 13 patients with severe autonomic 
failure secondary to post ganglionic neuronal denervation. Acarbose treatment 
reduced the post prandial fall in systolic blood pressure by 17mm Hg and the 
diastolic  drop by 9mmHg,  the  authors  report.  Heart  rate  response  did  not 
differ significantly between treatment and placebo groups. Acarbose provides 
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a novel pharmacological approach to treat this condition. 100mg of Acarbose 
taken 20 minutes before meals effectively attenuates the fall in blood pressure 
induced by meals in patients with severe autonomic failure.
 Dieter Neuser et al98, have screened safety and tolerability of Acarbose in the 
treatment of type I and type II diabetes mellitus. In this study 35% Acarbose 
and  24%  of  placebo  patient’s  adverse  events  were  the  main  reason  for 
withdrawal  in  Acarbose  recipients.  The  most  common  adverse  events  for 
Acarbose  recipients  were  gastrointestinal  (abdominal  pain,  flatulence  and 
diarrhea), which were more frequent than in placebo patients. These events 
occurred more often early in the study and attenuated over time. It concluded 
that Acarbose was safe and well tolerated by the majority of diabetic patients 
over a 1 year treatment period.
 Hucking k et al99 reported that Acarbose is able to enhance glucagons – like 
peptide -1 release and delay gastric emptying in normal subjects. The effect of 
alpha  –  glucosidase  inhibition  on  glucagons  like  peptide  -1  has  been  less 
evident in type 2 diabetic patients. The aim of this study was to investigate the 
possible influence of Acarbose on glucagons like peptide-1 release and gastric 
emptying in type 2 diabetic patients after mixed test meal. It concluded that 
hyper-glycaemic type 2 diabetic patients, ingestion of Acarbose with a mixed 
test  meal  failed  to  enhance  glucogon  like  peptide-1  release  and  did  not 
influence gastric emptying.
 Brunkhorst  M  et  al100, had  studied  Acarbose,  a  pseudomaltotetrasoe,  is 
produced by strains of genus Actionplanes. Acarbose synthesis is induced in 
the presence of maltose and maltotriose. The aim of the study to investigated 
the transport activities of maltose and maltotriose in actinoplanes sp. Results 
suggest that an Acarbose- insensitive maltose transporter  that also accepts 
maltodextrins  operates  in  Acarbose  –  grown  cells  while  a  maltodextrin 
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transporter that accepts maltose  and is moderately sensitive to Acarbose is 
found in cells grown in maltose / maltotriose containing media.
 Laurie  Barclay,  M.D,et  al101,   had  studied  liquid  chromatography  and 
capillary  zone  electrophoresis,  respectively  compiled  to  an  evaporate  right 
scattering detector and a vv detector have been developed for the analysis of 
Acarbose without any derivatization procedure. The electrophoretic separation 
of acarbose anomers was achieved through the manipulation of the working 
temperature. Both methods were validated and showed good validation data in 
terms  of  precision,  accuracy  and  linearity.  The  validated  methods  were 
successfully  applied  to  the  dosage  of  Acarbose  in  commercially  available 
glucobay tablets.
 Henrik  Wagner,  et  al102,  reported  that  the  chemistry  pharmacology, 
pharmacokinetics,  and clinical efficacy of Acarbose reviewed. It concluded 
that  the  Acarbose  is  efficacious  in  improving  metabolic  control  in  non- 
insulin- dependent diabetes mellitus. Further evaluation of its effects on the 
long – term complications of diabetes is needed. 
 Marija  Glavas  –  Dodav  et  al103, had  studied  liposome  gels  bearing  an 
antineoplastic agent, 5-fluorouracil, intended for topical application have been 
prepared and drug release properties invitro have been evaluated.
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3. Research Envisaged 
Objective of the study
 Diabetes mellitus continues to be one of the leading causes of death in the 
world particularly in India. Generally Oral anti – diabetic drug (Acarbose) have more 
frequency of dosing and low biological half life.
Hence reduce frequency of dosing and adverse effects without compromising 
the cure and relapse rates still remains a major goal for control policies.
Transfersomes prolongs the circulation of entrapped drug and protect the drug 
from metabolic  degradation.  Transfersomes  can  deform and  pass  through  narrow 
constriction of dermal layers without measurable loss. This high deformability gives 
better penetration of intact vesicles.
The  Acarbose  transfersomes  are  prepared  with  various  phospholipids 
concentration by film hydration method.
Further more, encapsulation of Acarbose in transfersomes may eliminate the 
inherent drawbacks experienced with oral administration of Acarbose.
Thus  the  present  study  was  undertaken  to  explore  the  encapsulation  of 
Acarbose, to characterize the transfersome for various physiochemical properties and 
their utility in diabetic treatment after topical administration 
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 Plan of the work
The following episodes are planned to carry out in this study.
1. To formulate the Acarbose transfersomes by film hydration method
2. To  observe  the  particle  size  and  size  distribution  of  the  prepared 
transfersomes.
3. To estimate the entrapped drug.
4. To test the stability of the formulated transfersomes.
5. To  observe  the  compatibility  of  the  product  and  excipients  used  in  the 
formulation.
6. To  examine  the  in  –  vitro diffusion  study  of  the  prepared  Acarbose 
transfersomes gel.
7. To perform the anti- diabetic activity of the Acarbose transfersomes gel.
8. To perform the skin irritation test for the Acarbose Transfersomes gel.
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4. DRUG AND EXCIPIENTS PROFILE
ACARBOSE104
 Molecular formulae          :  C25H43NO18                   
               
                                       
IUPAC Name              : Acarbose is designated by IUPAC rules as:
                                       O -4, 6-dideoxy- 4-[[(1S, 4R, 5S, 6S)-4, 5, 6-trihydroxy-
                                       3- (hydroxymethyl) -2-cyclohexen-1-yl] amino]- 
                                       α -D-glucopyranosyl - (1 → 4) - O -α-D- glucopyranosyl-
                                       (1 → 4)-D-glucose.
          Acarbose is an oral alpha-glucosidase inhibitor for use in the management of 
type  2  diabetes  mellitus.  Acarbose  is  an  oligosaccharide  which  is  obtained  from 
fermentation processes of a microorganism, Actinoplanes utahensis,
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 Synonym:                             Bay – g – 5421
 Brand names :                     Glicobase , precose
 p.Ka:                                     5.1
 Molecular Mass:                  645.6 gm/mol
 Category:                              Anti-diabetic
 Description :                         white amorphous powder
 Solubility :                             very soluble in water, soluble in methanol,  
                                                               ethanol.
 Mechanism of action:
Acarbose  inhibits  enzymes  (glycoside 
hydrolase’s)  needed  to  digest  carbohydrate: 
specifically  alpha-glucosidase enzymes  in  the 
brush  border  of  the  small  intestines  and 
pancreatic  alpha-amylase.  Pancreatic  alpha-
amylase  hydrolyzes  complex  starches  to 
oligosaccharide  in  the  lumen  of  the  small 
intestine,  whereas  the  membrane-bound 
intestinal  alpha-glycosidase  hydrolyzes 
oligosaccharide, trisaccharide, and disaccharide 
to  glucose  and  other  mono-saccharide  in  the 
small  intestine.  Inhibition  of  these  enzyme 
systems reduces the rate of digestion of complex 
63
carbohydrates. Less glucose is absorbed because 
the  carbohydrates  are  not  broken  down  into 
glucose  molecules.  In  diabetic  patients,  the 
short-term effect of these drugs therapies is to 
decrease current blood glucose levels: the long 
term effect is a small reduction in Hb level.
                                                    
Pharmacokinetic data: 
 Bio availability :                     Extremely low
 Metabolism:                           G.I.T
 Half life:                                 2hrs
 Excretion:                               Renal (less than 2%)
 Volume of distribution :         Steady state v.d is 0.32 L/Kg
 Protein binding:                 
                                                     Minimal protein binding with plasma- 
concentration of more than 1microgram /L and 
up to 98% with 0.08 microgram/L.
 Side effects:
Since  Acarbose  prevents  the  degradation  of 
complex  carbohydrates  in  to  glucose,  the 
carbohydrate will remain in the intestine; in the 
colon  bacteria  will  digest  the  complex 
carbohydrates  there by causing gastrointestinal 
side effects such as flatulence and diarrhea. 
Since these effects are dose related, it is 
generally advised to start with a low dose and 
gradually increase the dose to the desired 
amount.
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CONTRAINDICATIONS
Acarbose  is  contraindicated  in  patients  with 
known  hypersensitivity  to  the  drug  and  in 
patients with diabetic ketoacidosis or cirrhosis. 
Acarbose is also contraindicated in patients with 
inflammatory bowel disease, colonic ulceration, 
partial  intestinal  obstruction  or  in  patients 
predisposed  to  intestinal  obstruction.  In 
addition, Acarbose is contraindicated in patients 
who have chronic intestinal diseases associated 
with marked disorders of digestion or absorption 
and in  patients  who have conditions  that  may 
deteriorate as a result of increased gas formation 
in the intestine.
 Dose:                                      25, 50, 100 mg (t. i. d)
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1) Polyoxyethylene 20 Sorbitan Monopalmitate105
Synonym:
Molecular formula:
Molecular weight:
Description: 
Tween 40
C62 H122 O26
1284
Polysorbates  have a characterstic  odour and a  warm, 
some what bitter taste, yellow oily liquid at 250C
Solubility:  Soluble in ethanol, water 
Storage: Polysorbates  should  be  stored  in  a  Well-  closed 
container, protected from light, in a cool, dry place.
Application:  Polysorbates are also widely used in  cosmetics and 
fool  product,  emulsifying  agent,  solubilizing  agent, 
wetting agent 
 
2) Lecithin105
Synonym: Soybean Phospholipids
Description: Lecithin  vary  greatly  from  viscous   semiliquids  to 
powder depending   upon the free fatty acid content , 
colour may vary from brown to light yellow depending 
upon the degree purity.
Solubility: Lecithins  are  soluble  in  aliphatic  and  aromatic 
hydrocarbons,  mineral  oil    practically  insoluble  in 
water.
Storage: Lecithin  should  be  stored  in  well  closed   container 
protected from light and  oxidation
Application: Lecithins are mainly used in pharmaceutical prouducts 
as dispersing, emulsifying,  and stabilizing agents and 
are  included  in  intramuscular  and  intra  venous 
injections.
 
 3. Carbomer105
Synonym Carbopol
Description: Carbomers  are  white  –  coloured,  fluffy,  acidic, 
hygroscopic powders with a slight characteristic odour.
Melting points: 2600C
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Solubility: Soluble in  water  and after  neutralization,   in  ethanol 
(95%) and glycerin.
Application: Carbomers  are  mainly  used  in  liquid  or  semisolid 
pharmaceutical   formulations  as  suspending  or 
viscosity  –  increasing   agents.  Formulations  include 
creams,   gels  and  ointments  for  use   in  ophthalmic, 
rectal, and  topical preparations.
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5. MATERIALS AND METHODS
Table No.4   Materials Used 
S. No Materials Suppliers
1 Acarbose Orchid
2. Lecithin Himedia
3. Carbopol – 934 Kemphasol
4. Tween  40 S.D. Fine
5. Potassium  dihydrogen  Ortho 
phosphate
Ranbaxy
6. Disodium hydrogen phosphate Ranbaxy
7. Sodium hydroxide Nice
8 Triton x 100 Qualigens
9 Membrane Filter Sigma
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Table No.5 Equipments used
Preparation of reagents:
Preparation of phosphate buffer pH6.4:
             The phosphate buffer pH 6.4 was prepared by dissolving 2.38g of disodium 
hydrogen phosphate, 0.19g of potassium phosphate and 8.0g of sodium chloride in 
sufficient distilled water to produce 1000ml.  Adjust the pH if necessary.
S. No Equipments used Specification
1. Electronic Balance Sartorius
2. Magnetic Stirrer Remi
3. Rotary Flash evaporator Roteva
4. UV- Visible Spectrophotometer Shimadzu  UV – 1700
5. Ultra Sonic Processor Vibronics
6. pH meter Elico
7. Differential Scanning colorimetry
8. Laser particle counter Spectrex
9. Scanning electron microscopy Hitachi
10. FT-IR Perkin Elmer
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Standard Curve of Acarbose:
Preparation of Standard Curve of Acarbose:
              Weigh accurately about 0.1g of acarbose dissolve it in water to produce 
100ml. From the stock solution serial of concentrations 5, 10, 15, 20, 25µg/ml was 
taken by diluting the solution to 0.5, 1, 1.5, and 2, 2.5ml to make up to 10ml with 
phosphate buffer pH 6.4,  and measure  the absorbance of the resulting solution at 
maximum about 425 nm. It is shown in table no. 6, figure no. 3.
Table No.6 Standard Curve of Acarbose
                                a= 0.0088, b=0.0164, r=0.9975
                              
Concentration
(mcg/ml)
Absorbance
at 425nm
5 0.0892
10 0.164
15 0.236
20 0.34
25 0.426
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Standard Curve of Acarbose
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Fig No. 3 Standard Curve of Acarbose
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PREFORMULATION STUDIES
   Drug-Excipients interaction study
The  drug  and  excipients  were  analyzed  by  Fourier-Transform  I.R 
spectrophotometer. The interaction of drug with the excipients was identified through 
interpretation of I.R spectrums.
    Solubility Studies 
The  spontaneous  interaction  of  two  or  more  substance  to  form homogeneous 
molecular dispersion is called as solubility.  The solubility ofAcarbose was studied in 
various solvents.  Acarbose (10mg) was suspended separately in a 10 ml of different 
solvents at room temperature in tight closed test tube and shaken on wrist action.  The 
solubility of Acarbose in various solvents are follows 
 very soluble in water
  soluble in methanol & ethanol
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 PREPARATION OF TRANSFERSOMES106
                All methods of preparation of transfersomes are comprised of two steps.
 First,  a  thin  film  is  prepared,  sonicated  vesicles  are  homogenized  by  extrution 
through  a  membrane  filter.  The  mixture  of  vesicles  forming  ingredients,  that  is 
phospholipids and surfactant were dissolved in volatile organic solvent (chloroform-
methanol), organic solvent evaporated above the lipid transition temperature using a 
rotary evaporator. Final traces of solvent were removed under vaccum for overnight. 
The deposited lipid films were hydrated with buffer (6.4) by rotation at 60 rpm / min 
for 1hr at the corresponding temperature. The resulting vesicles were swollen for 2hr 
at room temperature .To prepare small vesicles; resulting LMVs were probe sonicated 
for 30 min at room temperature. The sonicated vesicles were homogenized by manual 
extrution through membrane filter.
Preparation of Topical Transfersome Gel Formulation:
Prepared transfersomes were incorporated in to carbopol-934 (1%) gel base in 
a 1:1 ratio. The carbopol-934 (1%) gel base prepared by soaking 30 min followed by 
continuous  stirring  with  water.1% carbopol-934  gel  base  has  a  good  consistency 
(gelling characteristic).
COMPATIBILITY STUDY
             The stability of a formulation depends upon the compatibility of the drug 
with the excipients. It is of significance to detect any possible physical (or) chemical 
interaction, since it can affect the bio-availability and stability of the drug. 
              Differential scanning calorimetry is a fast and reliable method to screen 
drug- excipients compatibility and provide maximum interaction.
Differential Scanning Calorimetry (DSC)
73
Differential Scanning calorimeter (Perkin – elmer) equipped with a monitor 
and a Computerized Thermal Analysis  System and printer were used. The instrument 
was calibrated with standard medium.
5-10  mg  of  samples  were  weighed  and  it  is  hermetically  sealed  in  flat-
bottomed alumininum pans. These samples were heated over a temperature range of 
50-5500C in an atmosphere of nitrogen (50 ml/min.) at a constant heating rate of 200C 
per minute, with almina being the reference standard.
DSC provide the gross idea about the possibility of interaction simply from 
visual comparison of the curves relevant to the individual excipient.
CHARACTERIZAITON OF TRANSFERSOMES
DETERMINATION OF PARTICLE SIZE
The particle size of Acarbose Transfersomes was viewed and photographed 
using Scanning electron microscopy. Acarbose Transfersomes were coated with gold 
by using Hitachi Vaccum evaporator. Coated samples were viewed and photographed 
in Hitachi s-3000H SEM. 
SIZE DISTRIBUTION OF TRANSFERSOMES
            Transfersomes were subjected in to laser particle counter (Spectrex make)  for 
characterizing size distribution of transfersomes.  
ENTRAPMENT EFFICIENCY 107
             The  entrapment  efficiency was  determined  by using  direct  method.  
Detergents are used to break the transfersome membranes1 ml of 0.1% Triton X-
100(Triton X-100 dissolved in phosphate buffer) was added to 0.1 ml Transfersomes 
preparations and made up to 5 ml with phosphate buffer then it was incubated at 37oC 
for 1.5 hrs to complete  breakup of the transfersome membrane and to release the 
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entrapped  material.  The  sample  was  filtered  through  a  Millipore  membrane  filter 
(0.25) µm. and the filtrate was measured at 425 nm for Acarbose. The amount of 
Acarbose was derived from the calibration curve.
 The entrapment efficiency is expressed as: 
                         Amount entrapped   
 Percentage Entrapment Efficiency   =                                   x 100                      
              Total amount added 
TRANSFERSOMES GEL EVALUATIONS
       Determination of viscosity
Viscosities  of  the  gels  were  determined  by  using  Brookfield  Viscometer 
(model- RVTP).Spindle type, RV-7 at 20 rpm. 100gm of the gel was taken in a 
beaker and the spindle was dipped in it and rotated for about 5 minutes and then 
reading was taken. 
      
        Extrudability
It is useful empirical test to measure the force required to extrude the material 
from the tube. The formulations were  filled in a collapsible metal tubes with a 
nasal tip of  5mm opening tube extrudability was then determined by measuring 
the amount of gel, extruded the tip when a pressure was applied on tube gel. The 
extrudability of the formulation was checked and the results were tabulated.
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STABILITY STUDY
           The formulated transfersome gels were divided in to 3 groups. These 3 
groups of transfersome gel formulation was filled in to aluminium collapsible tubes 
and stored at
a. Room temperature
b. 37± 5 o C
c. 4-5 o C
           The transfersome gel formulation was stored for a period of three months. 
Sample were withdrawn at every month for a period of three months and assessed for 
the  drug  content.  At  the  end  of  third  month  they  were  evaluated  for  physical 
parameter and integrity of the product.
1. Physical evaluation 
           The physical parameters considered for the evaluation were visual appearance, 
nature of the product, pH, viscosity, leak, phase separation and extrudability.
2. Chemical evaluation 
           The drug content of the formulation was estimated by withdrawing samples  
from different corners of the tube. The samples were mixed together and 1gm was 
taken  for  the  assay.  The  estimation  of  drug  content  was  carried  out  as  per  the 
procedure.
76
6.  IN VITRO DRUG RELEASE
Diffusion Study for Acarbose Transfersomes
         The in vitro release of Acarbose from the transfersome formulations were 
studied by open ended cylinder method. This diffusion cell  apparatus consist of a 
glass  tube  with  inner  diameter  of  2.5cm,  open  at  both  ends.  One  end  tied  with 
artificial membrane, which serves as a donor compartment.
              
          This study is performed for determining the permeation rate. The time needed 
to attain permeation flux at steady state and the information from in vitro studies were 
used to optimize the formulations.  Studies of drug release from transfersomes gel 
formulation  were performed using the  in  vitro diffusion method at370c,  100 rpm, 
within a period of 24hr. A weighed amount of prepared transfersomes gel formulation 
was poured in to  the glass cell  and diffused against  phosphate buffer  pH6.4 as a 
diffusion  medium.  Aliquots  were taken at  regular  intervals  and analyzed  spectro-
photometrically at 425nm using phosphate buffer pH 6.4 as blank.
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7. ANTI DIABETIC ACTIVITY
Antidiabetic  activity  of formulated  transfersomes  was carried  out  by using 
Albino rat as a animal model. The healthy albino rats of either sex were selected. The 
hair  on the dorsal side of rat  was shaved on he previous day of the experiments.  
Following an over night fast rats were divided 6 groups of 6 animals each and they 
were treated as follows.
Group I served as a control, which received normal saline, all other groups 
were  made  diabetic  by  an  intra  peritonial  injection  of  2%  alloxan  monohydrate 
(150mg/kg body weight). Group 2 received normal saline act as a Diabetic control.
Group – 3 received acarbose 50 mg/kg act as a standard. Group 4,5 and 6 received 
formulated transfersomes having entrapment efficiency 33.33% , 42.6% and 46.66% 
respectively which were mixed in 1gm of 1% carbopol -934 gel base. Treatment was 
started after 48 hrs  of alloxan administration and continued up to 15 days.
After 15 days the animals were sacrificed, the blood samples were collected 
1hr after the drug administration and tested for blood glucose level by using semi auto 
analyzer108.     
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8. SKIN IRRITATION TEST
The skin irritation was carried to evaluated hypersensitivity of transfersomes. 
The study was carried out by using albino rats. The albino rat were divided in to  6 
groups of 6 animals each. On the previous day of the experiment,  the hair on the 
dorsal  surface  of  rat  was  shaved.  Group  I  was  served  as  normal,  without  any 
treatment. Group II act as a control, which was applied with marketed adhesive tape. 
Group III act as a standard which was applied with 0.8% v/v aqueous solution of 
formalin (Standard irritant). Group IV, V, VI are act as a test which was applied with 
Acarbose trasfersomes gel formulations.  Acarbose transfersomes gels and formalin 
solution applied in to animal’s skin each day for 7 days109.
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9. RESULTS AND DISCUSSION
            Encapsulation of a drug in vesicular structures can be predicted to prolong the  
existence of the drug in the systemic circulation and thus enhance penetration in to 
target tissue, and perhaps reduce toxicity if selective uptake can be achieved.
            Transfersomes self-optimized aggregates, with the ultraflexible membrane,are 
able  to  deliver  the  drug  reproducibly  either  into  or  through  the  skin,  with  high 
efficiency.
Acarbose was chosen as the anti-diabetic type-2 (alpha-glucosidase inhibitor) 
drug  because  it  reduces  blood  glucose  level  without  producing  hypo-glycaemia, 
decreasing insulin level  compared to the sulfonylurea class of anti-diabetic  drugs. 
Acarbose,  when  given  orally  has  a  short  elimination  half  life  and  can  cause 
gastrointestinal  irritation,  abdominal  disturbance,  diarrhoea.  Frequent  oral 
administration of the drug is required for treatment.  Encapsulation of Acarbose may 
eliminate the inherent drawbacks experienced with oral administration of Acarbose.
              Hence Acarbose Transfersomes were formulated, evaluated, studied and 
concluded  that  long  circulation  time  of  the  formulation  accounts  for  its  superior 
therapeutic effectiveness.
               Acarbose encapsulated transfersomes were prepared by film-hydration 
method using rotary flash evaporator.
                Vesicle  size,  size  distribution  of  transfersomes,  percentage  drug 
entrapment, vesicle stability, drug with excipients interaction studies were evaluated. 
Also, the invitro release study through open tubular method with artificial membrane. 
                 Anti-diabetic activity of transfersomes were carried out in albino-rats 
bearing diabetic and parameters such as blood glucose level compared with standard. 
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PREFORMULATION STUDY
Drug-Excipients interaction study
 The drug Acarbose and the excipients namely lecithin,  tween-40, carbopol, 
were analyzed by Fourier-Transform I. R spectrophotometer. It is shown in 
the Figure no. 4, 5,6,7,8.
 The FT-IR spectrums were interpreted and it is shown there is no interaction 
between the drug with the excipients was conformed. It is shown in 
Table No. 7
CHARACTERIZATION OF TRANSFERSOMES
PARTICLE SIZE ANALYSIS OF TRANSFERSOMES
            The transfersomes were subjected to microscopic examination (S.E.M) for 
characterizing  size  and  shape  of  the  transfersomes.  Microscopic  examination 
revealed,  spherical  small  uni-lamellar  vesicles  of  270-650,  360-550,  290-550 size 
range,  for  Acarbose  transfersomes  of  3:2:1,  3:3:1,  3:4:1  ratios  respectively.  The 
average mean particle size of  formulation 1, 2 and 3 were 405nm, 455nm, 420nm 
respectively. Photographs were given in Figure. 9, 10, 11.
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                                                   Figure No.4
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FTIR SPECTRUM
Spectrum Name: Acarbose 
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                                                      Figure No.5
FTIR SPECTRUM
Spectrum Name: Tween-40 
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Figure No.6
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FTIR SPECTRUM
Spectrum Name: Carbopol-934 
Date: 08/14/2007
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Figure No.7
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Figure No.8
FTIR SPECTRUM
Spectrum Name: Lecithin 
Date: 08/14/2007
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Table: 7
FTIR SPECTRUM
Spectrum Name: Aca+Tween-40+Lec+Carbo 
Date: 08/14/2007
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IR-INTERPRETATION
     
Sample                             Functional groups(1/cm)
(OH)
alcoholic
-CH-
aromatic
C=O C-O-C -CH2
chain
-CH-
Acarbose     3389 2919 164
9
1152 ---- ----
Lecithin 3405 ---- ---- 1072 2360 2856
Tween-40 3430 2921 164
5
1105 ---- ----
Carbopol 3392 ---- 165
4
---- ---- 2920
Aca+Lec+Tw+Car 3389 2921 164
7
1102 2362 2921
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Compatibility Study
The  DSC  thermograms  of  acarbose,  lecithin,  tween-40,  carbopol-934  and 
physical mixture of  the above were obtained and compared. DSC trace combination 
is a simple superposition of the individual components traces, and incompatibility is 
highly  unlikely.  The appearance  of  extra-thermal  effects  in  the  DSC trace  or  the 
disappearance of one of the component peaks is an indication of an incompatibility. 
DSC thermograms of Acarbose alone (Graph.9) shows that an onset of  2900C 
and a maximum occurring at 1490C.
 DSC thermograms of Lecithin alone (Graph.10) shows that an onset of 2100C
and a maximum  occurring at 1600C
DSC thermograms of  Tween -40 alone  (Graph.11)  shows that  an onset  of 
1500C and a maximum  occurring at 700C
DSC thermograms of Carbopol  alone (Graph.12) shows that an onset of 560C 
and a maximum  occurring at 500C
The  Comparative  graph  13  shows  that  [physical  mixture  (1:1:1:1)  of 
Acarbose, Lecithin,  Tween-40, Carbopol ] there is no incompatibility between the 
drug and excipients.
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Figure No.9 
   DSC Thermogram of  Acarbose
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Figure No 10 
DSC Thermogram of Lecithin
Figure No. 11
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DSC Thermogram of Tween -40
Figure No. 12
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DSC Thermogram of Carbopol
Figure No . 13
DSC Thermogram of Carbopol, Tween-40, Acarbose, Lecithin (Physical mixture 1:1:1:1)
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Figure No.14
SEM Photograph of Acarbose Transfersomes (Formulation-1)
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Figure No.15
SEM Photograph of Acarbose Transfersomes (Formulation-2)
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                                                Figure No.16
SEM Photograph of Acarbose Transfersomes (Formulation-3)
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SIZE DISTRIBUTION OF TRANSFERSOMES
            Transfersomes  were subjected in  to  laser  particle  counter  (L.P.C) for 
characterizing size distribution of transfersomes.  Its shows that the particle size range 
200-700nm, 200-600nm, and 200-700 nm range for Acarbose transfersomes of 3:2:1, 
3:3:1, 3:4:1 ratios respectively.  The average mean particle size of formulation 1, 2 
and 3 were 420nm, 450nm, 430nm respectively. It is shown in Table No 8.
Table No.8
Particle size Distribution of Acarbose Transfersomes by using 
Laser Particle Counter
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ENTRAPMENT EFFICIENCY 
            The  formulation  variables  were  altered  and optimized  to  obtain  the 
transfersomes  with  maximum  drug  entrapment,  desired  transfersomal  size  and 
stability.   Increased  in  the  lipid  concentration  compared  to  drug entrapment  with 
increase  in  quantity  of  lipid  more  number  of  transfersomes  per  ml  of  the 
transfersomal  dispersion  were  formed,  resulting  in  to  an  increased  percent  drug 
entrapment.
            However, further increase in the lipid concentration had no proportionate 
increase in percentage drug entrapment due to approaching system saturation.
            Here 3:2:1,  3:3:1, 3:4:1ratios  were used to prepare transfersomes.  The 
percentage entrapment of transfersomes was found to be 33.33%, 42.6%, 46.66% for 
3:2:1, 3:3:1 and 3:4:1 respectively and 3:4:1 ratio found to have more entrapment 
efficiency compared to other two formulations.It is shown in Table No 9 and Figure 
No.12.
             Increasing the sonication time resulted in to reduction in percent drug 
entrapment; the decrease in percent drug entrapment is due to leakage of the drug 
during sonication.
S.NO. Acarbose Transfersomes
Formulations
Average particle 
Size Of Transfersomes
(nm)
1 Formulation-1             420
2 Formulation-2             450
3 Formulation-3              430
99
             Sonication brings about size reduction by breaking large transfersomes to 
smaller  ones  and  in  doing  so,  leakage  of  small  quantities  of  drug  from  the 
transfersomes occur.  Hence sonication time was optimized to 30 min,  and further 
reduction in the size by increasing sonication time was not attempted.
Table No.9
Percentage drug Entrapment of Acarbose Transfersomes
                                                                                                  n=3 (P<0.05)
S.No. Acarbose 
Transfersomes
Formulations
Percentage  of  Drug 
Entrapment
1 Formulation-1 33.33 ±2.2%
2 Formulation-2 42.6±1.8%
3 Formulation-3 46.66±1.2%
100
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
Formulation-1 Formulation-2 Formulation-3
COMPARATIVE ENTRAPMENT EFFICIENCY OF 
ACARBOSE TRANSFERSOME FORMULATIONS
PERCENTAGE
DRUG
ENTRAPMENT
Figure No.17
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Transfersomes Gel Evaluation
Determination of Viscosity
The viscosity of the gels was determined by using Brookfield viscometer. The 
viscosity of the formulations were ranged from 46,000 to 50,000cps and the results 
were shown in Table no 10
                                                         Table no 10
Formulation Viscosity in cps
Formulation-1 48,000
Formulation-2 48,500
Formulation-3 48,000
                                                                                    Average of three readings
  
 Extrudability
The extrudability of the gel formulations were checked as per the procedure, 
extrudability of carbopol gels was excellent. It is shown in Table no. 11
                                                 Table no. 11
Formulation Extrudability
Formulation-1 +++
Formulation-2 +++
Formulation-3 +++
                                                                                          +++Excellent 
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STABILITY STUDY
          The  stability  studies  of  transfersomal  formulation  were  carried  out  at  
refrigeration temperature (4oC), Room temperature and 37±5°C. Physical evaluation 
of prepared transfersomes gel shown in the Table no. 12.  Leakage of the drug from 
the prepared transfersome were analyzed in terms of percent drug retained storage 
under refrigerated condition showed  promising results of  98.2%, 94.5% and 95.5% 
for  formulation  1,  2,  3  respectively  after  3  month.  At  room  temperature  the 
percentage retained after 3 month was 94.28%, 87.98%, and 88.88% for formulation 
1, 2, 3 respectively and at 37oC the percentage of drug retained was 80.82%, 78.72%, 
and 79.64% for formulation 1, 2, 3 respectively. These showed that the formulation 
found to have more stable  at  refrigeration temperature,  where as good stability at 
room temperature and the drug degradation increased at 37oC. It is shown degradation 
increased at 37±5°C. It is shown in Table no. 13, 14 & 15.
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Table No.12
STABILITY STUDYPHYSICAL EVALUATION OF FORMULATIONS 
(TRANSFERSOMES IN 1%OF CARBOPOL GEL BASE)
PARAMETER ROOM TEMPERATURE 37±50C 4-50C
VISUAL APPEARANCE
 
 Initial
1month
2 month
3 month
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
pH
  Initial
1month
2 month
3 month
6.8
6.9
6.9
6.9
6.8
6.9
6.9
6.9
6.8
6.9
6.9
6.9
VISCOSITY
Initial
1month
2 month
3 month
48000
48000
48000
48000
48000
48000
48000
48000
48000
48000
48000
48000
EXTRUDABILITY
Initial
1month
2 month
3 month
Satisfactory
Satisfactory
satisfactory
Satisfactory
Satisfactory
Satisfactory
satisfactory
Satisfactory
Satisfactory
Satisfactory
satisfactory
Satisfactory
PHASE SEPARATION
Not found Not found Not found
LEAKAGE Not found Not found Not found
TEXTURE
Initial
1month
2 month
3 month
Smooth
Smooth  
Smooth
Smooth
Smooth
Smooth  
Smooth
Smooth
Smooth
Smooth  
Smooth
Smooth
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CHEMICAL EVALUATION OF FORMULATIONS (TRANSFERSOMES IN 
1%OF CARBOPOL GEL BASE)
Table No.13
Drug content (Formulation-1)
Storage conditions                                          Intervals
                                    (3 month study)
Initial 
(%)
1st month 
(%)
2nd month 
(%)
3rd month 
(%)
4-50C 100 99.34 98.66 98.20
Room temperature 100 97.30 95.60 94.28
37±50C 100 90.56 84.60 80.02
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Table No.14
Drug content-(Formulation-2)
Storage conditions
                                        Intervals
                                    (3 month study)
Initial 
(%)
1st month 
(%)
2nd month 
(%)
3rd month 
(%)
4-50C 100 98.5 96.5 94.5
Room temperature 100 98.5 92.5 87.98
37±50C 100 90.5 86.5 78.72
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Table No.15
 
                                           
Drug content (Formulation-3)
Storage conditions
                                         Intervals
                                    (3 month study)
Initial 
(%)
1st month 
(%)  
2nd month 
(%)  
3rd month 
(%)  
4-50C 100 97.5 96.5 95.5
Room temperature 100 92.5 90.45 88.88
37±50C 100 89.48 84.43 79.64
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INVITRO RELEASE STUDIES
In vitro release study is carried through open tubular method with artificial 
membrane  at370c, 100 rpm, within a period of 24hr.From this study we evaluated the 
percentage of drug diffused in the medium.The percentage of drug diffused from the 
Acarbose  transfersomes  were  70.62%,  73.35%,  84.70%,  from  transfersomes 
formulation 1, 2and 3 respectively at the end of 24hrs. It shown in Table  no 15,16 
and 17  Figure no. 13,14,15.  
The  results  showed  that  formulation  3  having  highest  entrapment  and 
maximum percentage of release. The comparative values are shown in the Table 18 
and Figure no 16.
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Table No.18
Invitro release study for Acarbose Tansfersomes Formulation-1
S.n
o 
Time 
in(hrs)
Absorbance at 
425nm
Concentration 
in(mcg/ml)
Amount in 
(mg)
%drug 
diffused
1 0.25 0.632 0 0 0
2 0.5 0.646 0 0 0
3 0.75 0.652 0 0 0
4 1 0.658 0.023 0.119 0.850
5 1.5 0.659 0.047 0.238 1.701
6 2 0.660 0.071 0.357 2.552
7 2.5 0.666 0.214 1.071 7.658
8 3 0.672 0.357 1.785 12.76
9 4 0.678 0.5 2.5 17.86
10 5 0.684 0.64 3.21 22.97
11 6 0.692 0.83 4.16 29.78
12 7 0.693 0.85 4.28 30.63
13 8 0.698 0.97 4.88 34.88
14 9 0.702 1.07 5.35 38.29
15 10 0.712 1.30 6.54 46.80
16 11 0.718 1.45 7.26 51.90
17 12 0.720 1.5 7.5 53.60
18 14 0.726 1.64 8.21 58.79
19 16 0.728 1.69 8.45 60.41
20 18 0.732 1.78 8.92 63.82
21 20 0.736 1.88 9.40 67.22
22 22 0.738 1.92 9.64 68.92
23 24 0.740 1.97 9.88 70.62
Figure no. 18
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Invitro Drug Release for Acarbose Transfersomes (Formulation-1)
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Table No.17
Invitro release study for Acarbose Transfersomes (Formulation-2)
S.n
o
Time in 
(hrs)
Absorbance at 
425nm 
Concentration in 
(mcg/ml)
Amount in 
(mg)
%drug in 
diffused
1 0.25 0.629 0 0 0
2 0.5 0.648 0 0 0
3 0.75 0.652 0 0 0
4 1 0.656 0 0 0
5 1.5 0.660 0.0714 0.35 3.53
6 2 0.665 0.190 0.95 9.61
7 2.5 0.669 0.285 1.42 14.43
8 3 0.670 0.309 1.54 15.6
9 4 0.672 0.357 1.78 18.03
10 5 0.677 0.476 2.38 24.05
11 6 0.684 0.642 3.21 32.46
12 7 0.685 0.666 3.33 33.67
13 8 0.688 0.738 3.69 37.27
14 9 0.692 0.833 4.16 42.08
15 10 0.695 0.904 4.52 45.69
16 11 0.696 0.928 4.64 46.89
17 12 0.699 1.00 5.00 50.50
18 14 0.701 1.04 5.23 52.91
19 16 0.708 1.21 6.07 61.32
20 18 0.711 1.28 6.42 64.93
21 20 0.712 1.30 6.54 66.13
22 22 0.716 1.40 7.02 70.94
23 24 0.718 1.45 7.26 73.35
Figure No. 19
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Invitro Drug Release for Acarbose Transfersomes (Formulation-2)
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Table No.16
Invitro release study for Acarbose Tansfersomes (Formulation-3)
S.n
o
Time 
in(hrs)
Absorbance at 
425 nm
Concentration in 
(mcg/ml)
Amount 
in(mg)
%drug 
diffused
1 0.25 0.632 0 0 0
2 0.5 0.646 0 0 0
3 0.75 0.652 0 0 0
4 1.00 0.658 0.023 0.119 0.930
5 1.5 0.659 0.047 0.238 1.861
6 2.00 0.661 0.095 0.476 3.72
7 2.5 0.672 0.357 1.785 13.96
8 3.00 0.678 0.5 2.5 19.54
9 4 0.688 0.73 3.69 28.85
10 5 0.699 1.00 5.00 35.09
11 6 0.704 1.11 5.59 43.74
12 7 0.706 1.16 5.83 45.60
13 8 0.708 1.21 6.07 47.47
14 9 0.711 1.28 6.42 50.26
15 10 0.718 1.45 7.26 56.77
16 11 0.720 1.5 7.5 58.63
17 12 0.721 1.52 7.61 59.57
18 14 0.726 1.64 8.21 64.22
19 16 0.729 1.71 8.57 67.01
20 18 0.730 1.73 8.69 67.94
21 20 0.738 1.92 9.64 75.39
22 22 0.742 2.02 10.11 79.11
23 24 0.748 2.16 10.83 84.70
Figure No.20
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Invitro Drug Release for Acarbose Transfersomes (Formulation-3)
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30
Time in Hrs
%
 D
ru
g 
D
iff
us
ed
%drug diffused
 Table No.19
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Comparative In vitro release study of Acarbose Transfersome formulations
S.No Acarbose Transfersome 
Formulations
% Drug diffused
1 Formulation-1 70.62
2 Formulation-2 73.35
3 Formulation-3 84.70
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Comparative In-vitro release study of Acarbose Transfersomes 
Formulations
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Figure No.21
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ANTI- DIABETIC ACTIVITY
The  blood  glucose  reducing  effect  was  significant  in  standard  (oral)  and 
Acarbose transfersome treated animal groups up to 15 days, compared with control 
group (P<0.05).  Acarbose (oral)  produced a  decrease  of  98 ± 5.4 (diabetic  mice, 
p<0.05 compared to diabetic control 255 ± 9.2) in blood glucose levels after 15 days. 
Acarbose transfersome formulations 1,2 and 3 (topical) produced a decrease of 140 ± 
4.6,  125 ± 2.1 and 110 ± 7.3 in  blood glucose levels  after  15 days  compared to 
diabetic control (P<0.05).
Table No.20
ANTI-DIABETIC ACTIVITY OF ACARBOSE 
TRANSFERSOMES GEL FORMULATIONS.
GROUPS FORMULATIONS GLUCOSE LEVEL AFTER 15 DAYS 
STUDY  (mg/dl)
1 CONTROL 90+5.4
2 DIABETIC 
CONTROL
255+9.2
3 STANDARD 98+5.4
4 FORMULATION-1 140+9.6
5 FORMULATION-2 125+2.9
6 FORMULATION-3 110+5.8
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Figure No.22
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Figure No. 23 Histopathalogical Details of Anti-Diabetic Activity of 
Acarbose Transfersomes gel
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SKIN IRRITATION TEST
Figure No.24 Skin Irritation Test – Before Irritation Test 
Figure No. 25 Skin Irritation Test - Standard Irritant (0.8 % v/v Formalin)
Figure No. 26 Skin Irritation Test – (USP adhesive tape)
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Figure No.27 Skin Irritation Test – Acarbose Transfersomes in Gel
The results  revealed  that  the  Acarbose  Transfersome gel  formulations  and 
adhesive tape has not showed any signs of inflammation at the rat skin after 7 days.
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 10. Conclusion
On the basis of  these results, the Acarbose trnasfersomes (Formulation-3) 
showed better characteristic behaviour.
The drug entrapment in formulation – 3 is higher than the other formulations. 
The  diffusion  study of  Acarbose  transfersome  gave  extended  release  of  the  drug 
which suffices to decreased dose, lesser frequent dose of treatment and more patient 
compliance.
In anti - diabetic studies, the formulation - 3 considerable decrease of blood 
glucose by topical application, when compared with other formulation. This proved 
its  targeting  efficiency.  So  it  was  concluded  that  Acarbose  transfersomes 
(Formulation – 3) was a better and efficient formulation than existing formulations. 
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